[{"role": "model", "parts": [{"text": "I am a large language model trained to be informative and comprehensive. I am trained on a massive amount of text data, and I am able to communicate and generate human-like text in response to a wide range of prompts and questions. For this task, I will act as a specialized assistant that can identify datasets mentioned in a publication and create a summary suitable for non-specialists.\n\nThe output should be a JSON array of objects, where each object has the following keys:\n- \"dataset_identifier\": This is any alphanumeric string (including punctuation marks) that uniquely identifies or provides access to a dataset.\n- \"repository_reference\": This is the URL or reference to the data repository where the dataset can be found.\n\nHere are some examples for reference:\n\n['dataset_identifier'=> 'EGAS00001000925', 'repository_reference'=> 'https=>//ega-archive.org/datasets/EGAS00001000925',\n 'dataset_identifier'=> 'GSE69091', 'repository_reference'=> 'https=>//www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69091',\n 'dataset_identifier'=> 'PRJNA306801', 'repository_reference'=> 'https=>//www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA306801',\n 'dataset_identifier'=> 'phs003416.v1.p1', 'repository_reference'=> 'dbGaP',\n 'dataset_identifier'=> 'PXD049309', 'repository_reference'=> 'https=>//www.ebi.ac.uk/pride/archive/projects/PXD049309',\n 'dataset_identifier'=> 'IPX0004230000', 'repository_reference'=> 'http=>//www.iprox.org',\n 'dataset_identifier'=> 'MSV000092944', 'repository_reference'=> 'https=>//massive.ucsd.edu/',\n 'dataset_identifier'=> 'n/a', 'repository_reference'=> 'https://data.broadinstitute.org/ccle_legacy_data/mRNA_expression/'\n]"}]}, {"role": "user", "parts": [{"text": "I have a webpage in HTML format (<html class=\"\" lang=\"en\"> <head> <link href=\"/static/assets/style-b3a36f11.css\" rel=\"stylesheet\"/> <link href=\"/static/assets/style-ef962842.css\" rel=\"stylesheet\"/> <link href=\"/static/assets/style-3ade8b5c.css\" rel=\"stylesheet\"/> <link href=\"/static/img/favicons/apple-touch-icon.png\" rel=\"apple-touch-icon\" sizes=\"180x180\"/> <link href=\"/static/img/favicons/favicon-48x48.png\" rel=\"icon\" sizes=\"48x48\" type=\"image/png\"/> <link href=\"/static/img/favicons/favicon-32x32.png\" rel=\"icon\" sizes=\"32x32\" type=\"image/png\"/> <link href=\"/static/img/favicons/favicon-16x16.png\" rel=\"icon\" sizes=\"16x16\" type=\"image/png\"/> <link href=\"/static/img/favicons/site.webmanifest\" rel=\"manifest\"/> <link color=\"#0071bc\" href=\"/static/img/favicons/safari-pinned-tab.svg\" rel=\"mask-icon\"/> <title> A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy - PMC </title> <link href=\"https://www.google-analytics.com\" rel=\"preconnect\"/> <link href=\"https://cdn.ncbi.nlm.nih.gov\" rel=\"preconnect\"/> <link href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5460863/\" rel=\"canonical\"/> </head> <body> <a class=\"usa-skipnav\" href=\"#main-content\"> Skip to main content </a> <section aria-label=\"Official website of the United States government\" class=\"usa-banner\"> <div class=\"usa-accordion\"> <header class=\"usa-banner__header\"> <div class=\"usa-banner__inner\"> <div class=\"grid-col-auto\"> <img alt=\"\" aria-hidden=\"true\" class=\"usa-banner__header-flag\" src=\"/static/img/us_flag.svg\"/> </div> <div aria-hidden=\"true\" class=\"grid-col-fill tablet:grid-col-auto\"> <p class=\"usa-banner__header-text\"> An official website of the United States government </p> <span class=\"usa-banner__header-action\"> Here's how you know </span> </div> <button aria-controls=\"gov-banner-default\" aria-expanded=\"false\" class=\"usa-accordion__button usa-banner__button\" type=\"button\"> <span class=\"usa-banner__button-text\"> Here's how you know </span> </button> </div> </header> <div class=\"usa-banner__content usa-accordion__content\" hidden=\"\" id=\"gov-banner-default\"> <div class=\"grid-row grid-gap-lg\"> <div class=\"usa-banner__guidance tablet:grid-col-6\"> <img alt=\"\" aria-hidden=\"true\" class=\"usa-banner__icon usa-media-block__img\" src=\"/static/img/icon-dot-gov.svg\"/> <div class=\"usa-media-block__body\"> <p> <strong> Official websites use .gov </strong> <br/> A <strong> .gov </strong> website belongs to an official government organization in the United States. </p> </div> </div> <div class=\"usa-banner__guidance tablet:grid-col-6\"> <img alt=\"\" aria-hidden=\"true\" class=\"usa-banner__icon usa-media-block__img\" src=\"/static/img/icon-https.svg\"/> <div class=\"usa-media-block__body\"> <p> <strong> Secure .gov websites use HTTPS </strong> <br/> A <strong> lock </strong> ( <span class=\"icon-lock\"> <svg aria-labelledby=\"banner-lock-description\" class=\"usa-banner__lock-image\" focusable=\"false\" height=\"64\" role=\"graphics-symbol\" viewbox=\"0 0 52 64\" width=\"52\" xmlns=\"http://www.w3.org/2000/svg\"> <title id=\"banner-lock-title\"> Lock </title> <desc id=\"banner-lock-description\"> Locked padlock icon </desc> <path d=\"M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z\" fill=\"#000000\" fill-rule=\"evenodd\"> </path> </svg> </span> ) or <strong> https:// </strong> means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. </p> </div> </div> </div> </div> </div> </section> <div class=\"usa-overlay\"> </div> <header class=\"usa-header usa-header--extended usa-header--wide\"> <div class=\"ncbi-header\"> <div class=\"ncbi-header__container\"> <a class=\"ncbi-header__logo-container\" href=\"https://www.ncbi.nlm.nih.gov/\"> <img alt=\" NCBI home page \" class=\"ncbi-header__logo-image\" src=\"/static/img/ncbi-logos/nih-nlm-ncbi--white.svg\"/> </a> <button aria-label=\"Show menu\" class=\"usa-menu-btn ncbi-header__hamburger-button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"ncbi-hamburger-icon\" fill=\"none\" focusable=\"false\" height=\"21\" viewbox=\"0 0 31 21\" width=\"31\" xmlns=\"http://www.w3.org/2000/svg\"> <path clip-rule=\"evenodd\" d=\"M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z\" fill=\"#F1F1F1\" fill-rule=\"evenodd\"> </path> </svg> </button> <div class=\"ncbi-header__desktop-buttons\"> <button aria-controls=\"search-field-desktop-navigation\" aria-expanded=\"false\" aria-label=\"Show search overlay\" class=\"usa-button usa-button--unstyled ncbi-header__desktop-button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#search\"> </use> </svg> Search </button> <div class=\"ncbi-header__login-dropdown\"> <button aria-controls=\"login-dropdown-menu\" aria-expanded=\"false\" aria-label=\"Show login menu\" class=\"usa-button usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#person\"> </use> </svg> <span> Log in </span> <svg aria-hidden=\"true\" class=\"usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#expand_less\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#expand_more\"> </use> </svg> </button> <ul class=\"usa-nav__submenu ncbi-header__login-dropdown-menu\" hidden=\"\" id=\"login-dropdown-menu\"> <li class=\"usa-nav__submenu-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/\"> Dashboard </a> </li> <li class=\"usa-nav__submenu-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/\"> Publications </a> </li> <li class=\"usa-nav__submenu-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/account/settings/\"> Account settings </a> </li> <li class=\"usa-nav__submenu-item\"> <button class=\"usa-button usa-button--outline ncbi-header__login-dropdown-logout-button\" type=\"button\"> Log out </button> </li> </ul> </div> </div> </div> </div> <div class=\"ncbi-search-panel ncbi--show-only-at-desktop\" hidden=\"\"> <div class=\"ncbi-search-panel__container\"> <form action=\"https://www.ncbi.nlm.nih.gov/search/all/\" aria-describedby=\"search-field-desktop-navigation-help-text\" autocomplete=\"off\" class=\"usa-search usa-search--big ncbi-search-panel__form\" method=\"GET\" role=\"search\"> <label class=\"usa-sr-only\" for=\"search-field-desktop-navigation\"> Search\u2026 </label> <input class=\"usa-input\" id=\"search-field-desktop-navigation\" name=\"term\" placeholder=\"Search NCBI\" type=\"search\" value=\"\"/> <button class=\"usa-button\" type=\"submit\"> <span class=\"usa-search__submit-text\"> Search NCBI </span> </button> </form> </div> </div> <nav aria-label=\"Primary navigation\" class=\"usa-nav\"> <p class=\"usa-sr-only\" id=\"primary-navigation-sr-only-title\"> Primary site navigation </p> <button aria-label=\"Close navigation menu\" class=\"usa-nav__close ncbi-nav__close-button\" type=\"button\"> <img alt=\"Close\" src=\"/static/img/usa-icons/close.svg\"/> </button> <form class=\"usa-search usa-search--small ncbi--hide-at-desktop margin-top-6\" role=\"search\"> <label class=\"usa-sr-only\" for=\"search-field\"> Search </label> <input class=\"usa-input\" id=\"search-field-mobile-navigation\" name=\"search\" placeholder=\"Search NCBI\" type=\"search\"/> <button class=\"usa-button\" type=\"submit\"> <img alt=\"Search\" class=\"usa-search__submit-icon\" src=\"data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg==\"/> </button> </form> <div class=\"ncbi-nav__mobile-login-menu ncbi--hide-at-desktop\" hidden=\"\"> <p class=\"ncbi-nav__mobile-login-menu-status\"> Logged in as: <strong class=\"ncbi-nav__mobile-login-menu-email\"> </strong> </p> <ul class=\"usa-nav__primary usa-accordion\"> <li class=\"usa-nav__primary-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/\"> Dashboard </a> </li> <li class=\"usa-nav__primary-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/\"> Publications </a> </li> <li class=\"usa-nav__primary-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/account/settings/\"> Account settings </a> </li> </ul> </div> <button class=\"usa-button ncbi-nav__mobile-login-button ncbi--hide-at-desktop\" type=\"button\"> Log in </button> </nav> </header> <section aria-label=\"PMC Header with search box\" class=\"pmc-header pmc-header--basic\"> <div class=\"pmc-nav-container\"> <div class=\"pmc-header__bar\"> <div class=\"pmc-header__logo\"> <a aria-label=\"PMC Home\" href=\"/\" title=\"Home\"> </a> </div> <button aria-label=\"Open search\" class=\"usa-button usa-button--unstyled pmc-header__search__button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 pmc-icon__open\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#search\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 pmc-icon__close\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#close\"> </use> </svg> </button> </div> <div class=\"pmc-header__search\"> <form autocomplete=\"off\" class=\"usa-search usa-search--extra usa-search--article-right-column pmc-header__search__form\" role=\"search\"> <label class=\"usa-sr-only\" for=\"pmc-search\"> Search PMC Full-Text Archive </label> <span class=\"autoComplete_wrapper flex-1\"> <input aria-autocomplete=\"both\" aria-controls=\"autoComplete_list_1\" aria-expanded=\"false\" aria-haspopup=\"true\" aria-owns=\"autoComplete_list_1\" class=\"usa-input width-full maxw-none\" id=\"pmc-search\" name=\"term\" placeholder=\"Search PMC Full-Text Archive\" required=\"required\" role=\"combobox\" type=\"search\"/> <ul aria-label=\"Suggestions\" hidden=\"\" id=\"autoComplete_list_1\" role=\"listbox\"> </ul> </span> <button class=\"usa-button\" formaction=\"https://www.ncbi.nlm.nih.gov/pmc/\" type=\"submit\"> <span class=\"usa-search__submit-text\"> Search in PMC </span> <img alt=\"Search\" class=\"usa-search__submit-icon\" src=\"/static/img/usa-icons-bg/search--white.svg\"/> </button> </form> <ul class=\"pmc-header__search__menu\"> <li> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/pmc/advanced/\"> Advanced Search </a> </li> <li> <a class=\"usa-link\" href=\"/journals/\"> Journal List </a> </li> <li> <a class=\"usa-link\" href=\"/about/userguide/\"> User Guide </a> </li> </ul> </div> </div> </section> <div class=\"usa-section padding-top-0 desktop:padding-top-6 pmc-article-section\"> <div aria-label=\"Actions bar\" class=\"grid-container pmc-actions-bar is-not-intersecting\" role=\"complementary\"> <div class=\"grid-row\"> <div class=\"grid-col-fill display-flex\"> <div class=\"display-flex\"> <ul class=\"usa-list usa-list--unstyled usa-list--horizontal\"> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex mob\"> <button aria-label=\"Open resources\" class=\"usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#more_vert\"> </use> </svg> </button> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex mob\"> <span class=\"usa-tooltip\"> <a aria-label=\"View on publisher site\" class=\"usa-link display-flex usa-tooltip__trigger\" href=\"https://doi.org/10.1371/journal.pone.0179170\" rel=\"noreferrer noopener\" role=\"button\" tabindex=\"0\" target=\"_blank\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#launch\"> </use> </svg> </a> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> View on publisher site </span> </span> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex\"> <span class=\"usa-tooltip\"> <a aria-label=\"Download PDF\" class=\"usa-link display-flex usa-tooltip__trigger\" href=\"pdf/pone.0179170.pdf\" role=\"button\" tabindex=\"0\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#file_download\"> </use> </svg> </a> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Download PDF </span> </span> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex\"> <span class=\"usa-tooltip\"> <button aria-label=\"Save article in MyNCBI collections.\" class=\"usa-button usa-button--unstyled collections-dialog-trigger collections-button display-flex collections-button-empty usa-tooltip__trigger\" tabindex=\"0\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 usa-icon--bookmark-full\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/action-bookmark-full.svg#icon\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 usa-icon--bookmark-empty\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/action-bookmark-empty.svg#icon\"> </use> </svg> </button> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Add to Collections </span> </span> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex\"> <span class=\"usa-tooltip\"> <button aria-label=\"Open dialog with citation text in different styles\" class=\"usa-button usa-button--unstyled citation-dialog-trigger display-flex usa-tooltip__trigger\" role=\"button\" tabindex=\"0\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 usa-icon--bookmark-empty\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#format_quote\"> </use> </svg> </button> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Cite </span> </span> </li> <li class=\"pmc-permalink display-flex\"> <span class=\"usa-tooltip\"> <button aria-expanded=\"false\" aria-haspopup=\"true\" aria-label=\"Show article permalink\" class=\"usa-button usa-button--unstyled display-flex usa-tooltip__trigger\" tabindex=\"0\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#share\"> </use> </svg> </button> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Permalink </span> </span> <div class=\"pmc-permalink__dropdown\" hidden=\"\"> <div class=\"pmc-permalink__dropdown__container\"> <h2 class=\"usa-modal__heading margin-top-0 margin-bottom-2\"> PERMALINK </h2> <div class=\"pmc-permalink__dropdown__content\"> <input aria-label=\"Article permalink\" class=\"usa-input\" type=\"text\" value=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5460863/\"/> <button aria-expanded=\"false\" class=\"usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0\" title=\"Copy article permalink\"> <svg aria-hidden=\"true\" class=\"usa-icon\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#content_copy\"> </use> </svg> <span class=\"margin-left-1\"> Copy </span> </button> </div> </div> </div> </li> </ul> </div> <button aria-label=\"Open article navigation\" class=\"usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#list\"> </use> </svg> </button> </div> </div> </div> <div class=\"grid-container desktop:padding-left-6\"> <div class=\"grid-row grid-gap\" id=\"article-container\"> <div class=\"grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content\"> <div class=\"grid-container padding-left-0 padding-right-0\"> <div class=\"grid-row desktop:margin-left-neg-6\"> <div class=\"grid-col-12\"> <div aria-label=\"Disclaimer note\" class=\"pmc-layout__disclaimer\" role=\"complementary\"> As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. <br/> Learn more: <a class=\"usa-link\" href=\"/about/disclaimer/\"> PMC Disclaimer </a> | <a class=\"usa-link\" href=\"/about/copyright/\"> PMC Copyright Notice </a> </div> </div> </div> <div class=\"grid-row pmc-wm desktop:margin-left-neg-6\"> <main class=\"usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0\" id=\"main-content\"> <section aria-label=\"Journal banner\" class=\"pmc-journal-banner text-center line-height-none\"> <img alt=\"PLOS ONE logo\" height=\"75\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-plosone.png\" usemap=\"#pmc-banner-imagemap\" width=\"500\"/> <map name=\"pmc-banner-imagemap\"> <area alt=\"Link to PLOS ONE\" href=\"https://doi.org/10.1371/journal.pone.0179170\" rel=\"noopener noreferrer\" shape=\"default\" target=\"_blank\" title=\"Link to PLOS ONE\"/> </map> </section> <article lang=\"en\"> <section aria-label=\"Article citation and metadata\"> <section class=\"pmc-layout__citation font-secondary font-xs\"> <div> <div class=\"display-inline-block\"> <button aria-controls=\"journal_context_menu\" aria-expanded=\"false\" class=\"cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary\" type=\"button\"> PLoS One </button> </div> . 2017 Jun 6;12(6):e0179170. doi: <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1371/journal.pone.0179170\" rel=\"noopener noreferrer\" target=\"_blank\"> 10.1371/journal.pone.0179170 </a> </div> <nav hidden=\"hidden\" id=\"journal_context_menu\"> <ul class=\"menu-list font-family-ui\" role=\"menu\"> <li role=\"presentation\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/pmc/?term=%22PLoS%20One%22%5Bjour%5D\" role=\"menuitem\"> Search in PMC </a> </li> <li role=\"presentation\"> <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22PLoS%20One%22%5Bjour%5D\" lang=\"en\" role=\"menuitem\"> Search in PubMed </a> </li> <li role=\"presentation\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22PLoS%20One%22%5BTitle%20Abbreviation%5D\" role=\"menuitem\"> View in NLM Catalog </a> </li> <li role=\"presentation\"> <a class=\"usa-link\" href=\"?term=%22PLoS%20One%22%5Bjour%5D\" role=\"menuitem\"> Add to search </a> </li> </ul> </nav> </section> <section class=\"front-matter\"> <div class=\"ameta p font-secondary font-xs\"> <hgroup> <h1> A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy </h1> </hgroup> <div class=\"cg p\"> <a aria-describedby=\"id1\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Weiss%20GJ%22%5BAuthor%5D\"> <span class=\"name western\"> Glen J Weiss </span> </a> <div hidden=\"hidden\" id=\"id1\"> <h3> <span class=\"name western\"> Glen J Weiss </span> </h3> <div class=\"p\"> <sup> 1 </sup> Western Regional Medical Center, Cancer Treatment Centers of America, Goodyear, Arizona, United States of America </div> <div class=\"p\"> <sup> 2 </sup> Translational Genomics Research Institute, Phoenix, Arizona, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Weiss%20GJ%22%5BAuthor%5D\"> <span class=\"name western\"> Glen J Weiss </span> </a> </div> </div> <sup> 1, </sup> <sup> 2, </sup> <sup> * </sup> , <a aria-describedby=\"id2\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Byron%20SA%22%5BAuthor%5D\"> <span class=\"name western\"> Sara A Byron </span> </a> <div hidden=\"hidden\" id=\"id2\"> <h3> <span class=\"name western\"> Sara A Byron </span> </h3> <div class=\"p\"> <sup> 2 </sup> Translational Genomics Research Institute, Phoenix, Arizona, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Byron%20SA%22%5BAuthor%5D\"> <span class=\"name western\"> Sara A Byron </span> </a> </div> </div> <sup> 2 </sup> , <a aria-describedby=\"id3\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Aldrich%20J%22%5BAuthor%5D\"> <span class=\"name western\"> Jessica Aldrich </span> </a> <div hidden=\"hidden\" id=\"id3\"> <h3> <span class=\"name western\"> Jessica Aldrich </span> </h3> <div class=\"p\"> <sup> 2 </sup> Translational Genomics Research Institute, Phoenix, Arizona, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Aldrich%20J%22%5BAuthor%5D\"> <span class=\"name western\"> Jessica Aldrich </span> </a> </div> </div> <sup> 2 </sup> , <a aria-describedby=\"id4\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Sangal%20A%22%5BAuthor%5D\"> <span class=\"name western\"> Ashish Sangal </span> </a> <div hidden=\"hidden\" id=\"id4\"> <h3> <span class=\"name western\"> Ashish Sangal </span> </h3> <div class=\"p\"> <sup> 1 </sup> Western Regional Medical Center, Cancer Treatment Centers of America, Goodyear, Arizona, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Sangal%20A%22%5BAuthor%5D\"> <span class=\"name western\"> Ashish Sangal </span> </a> </div> </div> <sup> 1 </sup> , <a aria-describedby=\"id5\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Barilla%20H%22%5BAuthor%5D\"> <span class=\"name western\"> Heather Barilla </span> </a> <div hidden=\"hidden\" id=\"id5\"> <h3> <span class=\"name western\"> Heather Barilla </span> </h3> <div class=\"p\"> <sup> 1 </sup> Western Regional Medical Center, Cancer Treatment Centers of America, Goodyear, Arizona, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Barilla%20H%22%5BAuthor%5D\"> <span class=\"name western\"> Heather Barilla </span> </a> </div> </div> <sup> 1 </sup> , <a aria-describedby=\"id6\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Kiefer%20JA%22%5BAuthor%5D\"> <span class=\"name western\"> Jeffrey A Kiefer </span> </a> <div hidden=\"hidden\" id=\"id6\"> <h3> <span class=\"name western\"> Jeffrey A Kiefer </span> </h3> <div class=\"p\"> <sup> 2 </sup> Translational Genomics Research Institute, Phoenix, Arizona, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Kiefer%20JA%22%5BAuthor%5D\"> <span class=\"name western\"> Jeffrey A Kiefer </span> </a> </div> </div> <sup> 2, </sup> <sup> \u00a4a </sup> , <a aria-describedby=\"id7\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Carpten%20JD%22%5BAuthor%5D\"> <span class=\"name western\"> John D Carpten </span> </a> <div hidden=\"hidden\" id=\"id7\"> <h3> <span class=\"name western\"> John D Carpten </span> </h3> <div class=\"p\"> <sup> 2 </sup> Translational Genomics Research Institute, Phoenix, Arizona, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Carpten%20JD%22%5BAuthor%5D\"> <span class=\"name western\"> John D Carpten </span> </a> </div> </div> <sup> 2, </sup> <sup> \u00a4b </sup> , <a aria-describedby=\"id8\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Craig%20DW%22%5BAuthor%5D\"> <span class=\"name western\"> David W Craig </span> </a> <div hidden=\"hidden\" id=\"id8\"> <h3> <span class=\"name western\"> David W Craig </span> </h3> <div class=\"p\"> <sup> 2 </sup> Translational Genomics Research Institute, Phoenix, Arizona, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Craig%20DW%22%5BAuthor%5D\"> <span class=\"name western\"> David W Craig </span> </a> </div> </div> <sup> 2, </sup> <sup> \u00a4b, </sup> <sup> \u2021 </sup> , <a aria-describedby=\"id9\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Whitsett%20TG%22%5BAuthor%5D\"> <span class=\"name western\"> Timothy G Whitsett </span> </a> <div hidden=\"hidden\" id=\"id9\"> <h3> <span class=\"name western\"> Timothy G Whitsett </span> </h3> <div class=\"p\"> <sup> 2 </sup> Translational Genomics Research Institute, Phoenix, Arizona, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Whitsett%20TG%22%5BAuthor%5D\"> <span class=\"name western\"> Timothy G Whitsett </span> </a> </div> </div> <sup> 2, </sup> <sup> \u00a4c, </sup> <sup> \u2021 </sup> </div> <div class=\"cg p\"> Editor: <span class=\"name western\"> Daniele Santini </span> <sup> 3 </sup> </div> <ul class=\"d-buttons inline-list\"> <li> <button aria-controls=\"aip_a\" aria-expanded=\"false\" class=\"d-button\"> Author information </button> </li> <li> <button aria-controls=\"anp_a\" aria-expanded=\"false\" class=\"d-button\"> Article notes </button> </li> <li> <button aria-controls=\"clp_a\" aria-expanded=\"false\" class=\"d-button\"> Copyright and License information </button> </li> </ul> <div class=\"d-panels font-secondary-light\"> <div class=\"d-panel p\" id=\"aip_a\"> <div class=\"p\" id=\"aff001\"> <sup> 1 </sup> Western Regional Medical Center, Cancer Treatment Centers of America, Goodyear, Arizona, United States of America </div> <div id=\"aff002\"> <sup> 2 </sup> Translational Genomics Research Institute, Phoenix, Arizona, United States of America </div> <div id=\"edit1\"> <sup> 3 </sup> Universita Campus Bio-Medico di Roma, ITALY </div> <div class=\"author-notes p\"> <div class=\"fn\" id=\"coi001\"> <p> <strong> Competing Interests: </strong> TGW holds patents (US Patent No.9,404,927 B2) and provisional patents (US Provisional Patent Application no. PCT/US2015/062785)-unrelated to this work and SAB holds patents (US Patent No. 9,140,689) or provisional patents (US Provisional Patent Application no. PCT/US2016/037292)-unrelated to this work. This does not alter our adherence to PLOS ONE policies on sharing data and materials. </p> </div> <div class=\"fn\" id=\"fn2\"> <div class=\"p\"> <ul class=\"list\"> <li> <div class=\"p\"> <strong> Conceptualization: </strong> GJW JDC DWC. </div> </li> <li> <div class=\"p\"> <strong> Data curation: </strong> GJW SAB JA AS HB TGW. </div> </li> <li> <div class=\"p\"> <strong> Formal analysis: </strong> GJW SAB JK JA JDC DWC TGW. </div> </li> <li> <div class=\"p\"> <strong> Funding acquisition: </strong> GJW JDC DWC. </div> </li> <li> <div class=\"p\"> <strong> Investigation: </strong> GJW SAB JA AS HB JK JDC DWC TGW. </div> </li> <li> <div class=\"p\"> <strong> Methodology: </strong> GJW SAB JA JK JDC DWC TGW. </div> </li> <li> <div class=\"p\"> <strong> Project administration: </strong> GJW DWC TGW. </div> </li> <li> <div class=\"p\"> <strong> Resources: </strong> GJW SAB JA AS HB JK JDC DWC TGW. </div> </li> <li> <div class=\"p\"> <strong> Supervision: </strong> GJW DWC TGW. </div> </li> <li> <div class=\"p\"> <strong> Validation: </strong> GJW SAB JA JK JDC DWC TGW. </div> </li> <li> <div class=\"p\"> <strong> Visualization: </strong> GJW SAB JA JDC DWC TGW. </div> </li> <li> <div class=\"p\"> <strong> Writing \u2013 original draft: </strong> GJW SAB JA JK JDC DWC TGW. </div> </li> <li> <div class=\"p\"> <strong> Writing \u2013 review &amp; editing: </strong> GJW SAB JA AS HB JK JDC DWC TGW. </div> </li> </ul> </div> </div> <div class=\"fn\" id=\"currentaff001\"> <sup> \u00a4a </sup> <p class=\"display-inline\"> Current address: Systems Oncology, Scottsdale, Arizona, United States of America </p> </div> <div class=\"fn\" id=\"currentaff002\"> <sup> \u00a4b </sup> <p class=\"display-inline\"> Current address: Department of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, California, United Stated of America </p> </div> <div class=\"fn\" id=\"currentaff003\"> <sup> \u00a4c </sup> <p class=\"display-inline\"> Current address: Norton Thoracic Institute, St. Joseph\u2019s Hospital and Medical Center, Dignity Health, Phoenix, Arizona, United States of America </p> </div> <div class=\"fn\" id=\"econtrib001\"> <p> \u2021 DWC and TGW are Joint Senior Authors. </p> </div> <div class=\"fn\" id=\"cor001\"> <sup> \u2709 </sup> <p class=\"display-inline\"> * E-mail: <span> glen.weiss@ctca-hope.com </span> </p> </div> </div> <h4 class=\"font-secondary\"> Roles </h4> <div class=\"p\"> <strong class=\"contrib\"> <span class=\"name western\"> Daniele Santini </span> </strong> : <span class=\"role\"> Editor </span> </div> </div> <div class=\"d-panel p\" id=\"anp_a\"> <div class=\"notes p\"> <section class=\"history\" id=\"historyarticle-meta1\"> <p> Received 2017 Mar 1; Accepted 2017 May 19; Collection date 2017. </p> </section> </div> </div> <div class=\"d-panel p\" id=\"clp_a\"> <div> \u00a9 2017 Weiss et al </div> <p> This is an open access article distributed under the terms of the <a class=\"usa-link usa-link--external\" href=\"http://creativecommons.org/licenses/by/4.0/\" rel=\"noopener noreferrer\" target=\"_blank\"> Creative Commons Attribution License </a> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. </p> <div class=\"p\"> <a class=\"usa-link\" href=\"/about/copyright/\"> PMC Copyright notice </a> </div> </div> </div> <div> PMCID: PMC5460863 PMID: <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/28586388/\"> 28586388 </a> </div> </div> </section> </section> <section aria-label=\"Article content\"> <section class=\"body main-article-body\"> <section class=\"abstract\" id=\"abstract1\"> <h2> <a class=\"usa-anchor\" id=\"abstract1-anchor\"> </a> Abstract </h2> <section id=\"sec001\"> <h3 class=\"pmc_sec_title\"> Background </h3> <p> Small cell lung cancer (SCLC) that has progressed after first-line therapy is an aggressive disease with few effective therapeutic strategies. In this prospective study, we employed next-generation sequencing (NGS) to identify therapeutically actionable alterations to guide treatment for advanced SCLC patients. </p> </section> <section id=\"sec002\"> <h3 class=\"pmc_sec_title\"> Methods </h3> <p> Twelve patients with SCLC were enrolled after failing platinum-based chemotherapy. Following informed consent, genome-wide exome and RNA-sequencing was performed in a CLIA-certified, CAP-accredited environment. Actionable targets were identified and therapeutic recommendations made from a pharmacopeia of FDA-approved drugs. Clinical response to genomically-guided treatment was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. </p> </section> <section id=\"sec003\"> <h3 class=\"pmc_sec_title\"> Results </h3> <p> The study completed its accrual goal of 12 evaluable patients. The minimum tumor content for successful NGS was 20%, with a median turnaround time from sample collection to genomics-based treatment recommendation of 27 days. At least two clinically actionable targets were identified in each patient, and six patients (50%) received treatment identified by NGS. Two had partial responses by RECIST 1.1 on a clinical trial involving a PD-1 inhibitor + irinotecan (indicated by <em> MLH1 </em> alteration). The remaining patients had clinical deterioration before NGS recommended therapy could be initiated. </p> </section> <section id=\"sec004\"> <h3 class=\"pmc_sec_title\"> Conclusions </h3> <p> Comprehensive genomic profiling using NGS identified clinically-actionable alterations in SCLC patients who progressed on initial therapy. Recommended PD-1 therapy generated partial responses in two patients. Earlier access to NGS guided therapy, along with improved understanding of those SCLC patients likely to respond to immune-based therapies, should help to extend survival in these cases with poor outcomes. </p> </section> </section> <section id=\"sec005\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"sec005-anchor\"> </a> Introduction </h2> <p> Lung cancer is the leading cause of cancer deaths in both women and men in the United States and throughout the world. In 2017, it is expected that there will be 222,500 new cases of lung cancer with more than 155,000 deaths in the United States alone [ <a aria-describedby=\"pone.0179170.ref001\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref001\"> 1 </a> ]. As small cell lung cancer (SCLC) accounts for between 13\u201315% of lung cancer, ~30,000 new cases will be diagnosed in the US in 2017 [ <a aria-describedby=\"pone.0179170.ref002\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref002\"> 2 </a> , <a aria-describedby=\"pone.0179170.ref003\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref003\"> 3 </a> ]. Though initially responsive to front-line chemotherapy, the vast majority of SCLC will have disease progression (PD). For SCLC patients who progress after first-line therapy, the standard FDA-approved treatment options are either topotecan or the combination of cyclophosphamide, doxorubicin, and vincristine (CAV) [ <a aria-describedby=\"pone.0179170.ref003\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref003\"> 3 </a> , <a aria-describedby=\"pone.0179170.ref004\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref004\"> 4 </a> ]. Response rates for PD are substantially lower, and have been reported as low as 7% for oral topotecan in cisplatin-refractory patients or 8\u201315% for CAV [ <a aria-describedby=\"pone.0179170.ref005\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref005\"> 5 </a> , <a aria-describedby=\"pone.0179170.ref006\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref006\"> 6 </a> ]. In a phase III trial for second-line treatment for SCLC, amrubicin and topotecan had response rates of 31.1 and 16.9%, respectively, with no change in overall survival (7.5\u20137.8 months) or progression-free survival (3.5\u20134.1 months) [ <a aria-describedby=\"pone.0179170.ref007\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref007\"> 7 </a> ]. SCLC, especially extensive-stage, that has progressed after 1 <sup> st </sup> line therapy has few effective treatments and no new class of approved therapies in decades [ <a aria-describedby=\"pone.0179170.ref008\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref008\"> 8 </a> ]. </p> <p> While non-small cell lung cancers (NSCLC) harbor recurrent oncogenic mutations that can be targeted therapeutically (e.g. epidermal growth factor receptor ( <em> EGFR </em> ) or anaplastic lymphoma receptor tyrosine kinase ( <em> ALK </em> )) [ <a aria-describedby=\"pone.0179170.ref009\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref009\"> 9 </a> ], the most prevalent molecular alterations in SCLC are in <em> TP53 </em> , <em> RB1 </em> , and <em> MYC </em> , alterations without effective targeted therapies [ <a aria-describedby=\"pone.0179170.ref010\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref010\"> 10 </a> ]. Another group recently interrogated 148 lung neuroendocrine tumors, including 33 SCLC, and demonstrated the prevalence of <em> TP53 </em> and <em> RB1 </em> while suggesting significant roles for chromatin-remodeling genes in lung neuroendocrine pathogenesis [ <a aria-describedby=\"pone.0179170.ref011\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref011\"> 11 </a> ]. Alterations in PI3K signaling (especially <em> PIK3CA </em> ) were suggested for therapeutic targeting in carcinomas, although the pathway was altered in a subset of tumors (11.7%). While novel, targeted therapeutics against NOTCH signaling, PI3K-PTEN pathway, and FGFR proteins have shown pre-clinical promise, survival rates for recurrent, extensive-stage SCLC remain dismal [ <a aria-describedby=\"pone.0179170.ref012\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref012\"> 12 </a> , <a aria-describedby=\"pone.0179170.ref013\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref013\"> 13 </a> ]. More recently, immune checkpoint inhibitors have shown efficacy in SCLC with PD-1 inhibition via pembrolizumab demonstrating a response rates of 35% in a phase I/II trial of SCLC patients[ <a aria-describedby=\"pone.0179170.ref014\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref014\"> 14 </a> ], while nivolumab had a response rate of 10% as a single agent or 19\u201323% in combination with ipilimumab in patients with relapsed SCLC [ <a aria-describedby=\"pone.0179170.ref015\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref015\"> 15 </a> ]. Thus, a deeper understanding of the driver alterations in SCLC, especially in PD, and an understanding of those patients likely to respond to immune checkpoint blockade should improve patient outcome. </p> <p> We know that somatic alterations (i.e., point mutations, small insertions and deletions, rearrangements, gains and losses) occur at the DNA level in cancer. These somatic events can drive tumorigenesis, metastatic progression, and/or drug resistance. More importantly, specific somatic alterations can be targeted by therapeutics. For the first time, technology now offers us the ability to survey the global somatic landscape of cancer: it is possible to sequence, analyze, and compare the matched tumor and normal genomes of an individual patient. The focus of the current study is to improve treatment strategies for individuals with SCLC, especially with PD. We recently completed a pilot study (NFCR trial) for patients with advanced rare cancers ( <a class=\"usa-link\" href=\"https://clinicaltrials.gov/ct2/show/NCT01443390\" rel=\"noopener noreferrer\" target=\"_blank\"> NCT01443390 </a> ) to evaluate the utility of identifying potential therapeutic targets in tumors from patients whose cancers had progressed on standard therapies. Our preliminary findings in advanced cancer using next-generation sequencing (NGS) indicate most tumors possess at least one actionable target for a conventional FDA-approved agent or a drug in clinical development [ <a aria-describedby=\"pone.0179170.ref016\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref016\"> 16 </a> ]. Paired tumor-normal exome and transcriptome sequencing efficiency, coverage, cost, and analytics has improved over the last decade and is being applied in the clinic. </p> <p> In this prospective study, we employed genome-wide exome and RNA-sequencing to identify genomic events and associated expression changes in advanced SCLC, and sought to prescribe systemic therapies based on the results. </p> </section> <section id=\"sec006\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"sec006-anchor\"> </a> Materials and methods </h2> <section id=\"sec007\"> <h3 class=\"pmc_sec_title\"> Study design </h3> <p> The rationale for this study is that NGS could be used to identify as many potentially actionable genomic abnormalities that could be targeted using available therapies in advanced SCLC patients. This single center, prospective, single-arm study was in patients with advanced SCLC that progressed on 1 <sup> st </sup> line standard systemic therapy. The study was conducted in accordance with the Declaration of Helsinki and was approved by the Western Institutional Review Board (WIRB <sup> \u00ae </sup> Protocol #20132159) (clinicaltrials.gov <a class=\"usa-link\" href=\"https://clinicaltrials.gov/ct2/show/NCT02297087\" rel=\"noopener noreferrer\" target=\"_blank\"> NCT02297087 </a> ) on September 15, 2014. Study enrollment was between October 2014 and April 2016 and last follow-up was completed in February 2017 ( <a class=\"usa-link\" href=\"#pone.0179170.s002\"> S1 File </a> ). The study was registered on clinicaltrials.gov within 21 days of enrollment of the first participant in compliance with FDAAA 801 requirements. The authors confirm that all ongoing and related trials for this drug/intervention are registered. Each participant signed informed consent before study related procedures were conducted. To participate, patients must have been age \u226518 and willing to undergo a fresh tumor biopsy. Other eligibility criteria included: Karnofsky performance status \u226570%, life expectancy &gt;3 months, and baseline laboratory data indicating acceptable bone marrow reserve, liver, and renal function. Main exclusion criteria were symptomatic or untreated central nervous system (CNS) metastases, known active infections requiring intravenous antimicrobial therapy, pregnant or breast-feeding women, or tumor that was inaccessible for an adequate biopsy. Participation on another clinical trial involving treatment prior to or during participation on this study was allowed. Clinical annotation related to the tumor samples analyzed such as age at time of consent, gender, histology, stage at the time of consent, type of prior therapy, and duration and best response to those therapies were collected and summarized. </p> </section> <section id=\"sec008\"> <h3 class=\"pmc_sec_title\"> Genome-wide exome and mRNA-sequencing analysis </h3> <p> Following patient consent, fresh frozen tumor tissue was acquired by clinical tumor biopsy for profiling analysis, and peripheral blood mononuclear cells collected for constitutional DNA analysis. Specimens were de-identified and coded, and shipped overnight to Ashion <sup> \u00ae </sup> ( <a class=\"usa-link usa-link--external\" href=\"http://www.ashion.com\" rel=\"noopener noreferrer\" target=\"_blank\"> http://www.ashion.com </a> ), a Clinical Laboratory Improvement Amendments (CLIA)-certified, College of American Pathologists (CAP)-accredited laboratory, for sample processing and analysis. A board-certified pathologist at Ashion reviewed a portion of each specimen to confirm adequate tumor content (&gt;20% tumor). DNA and RNA were extracted, and genome-wide exome sequencing and RNA-sequencing was performed by Ashion <sup> \u00ae </sup> using their GEM Genome Wide (GEM GW) exome sequencing and RNA-sequencing platforms. Tumor/normal GEM GW exome sequencing was used to provide clinical whole exome analysis for identification of somatic coding point mutations, small insertions, and deletions within exons for &gt;20,000 genes, and for regional whole genome analysis to detect copy number changes and structural events. Tumor RNA-sequencing was performed for fusion detection. Comparison to commercially available normal lung RNA was used for differential expression. The average GEM GW exome target coverage was 420X (range, 222X-560X) for tumor samples and 201X (range, 118X-270X) for peripheral blood samples. For tumor samples, all samples had more than 95% of target bases covered with at least 20X coverage (average 98.1%, range 97.9\u201398.3%). More than 80% of target bases had at least 100X coverage (average 92.5%, range 81.7\u201395.9%). Tumor RNA-sequencing had an average of &gt;248 million aligned reads (range, 170\u2013377 million). Sequence alignment, variant calling, and variant filtering were performed using a custom bioinformatics pipeline, as previously described [ <a aria-describedby=\"pone.0179170.ref017\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref017\"> 17 </a> \u2013 <a aria-describedby=\"pone.0179170.ref019\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref019\"> 19 </a> ]. Data were aligned to build 37 of the human reference genome. Data are deposited to dbGaP under accession, phs001366.v1.p1. ( <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001366.v1.p1\" rel=\"noopener noreferrer\" target=\"_blank\"> https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001366.v1.p1 </a> ). </p> </section> <section id=\"sec009\"> <h3 class=\"pmc_sec_title\"> Genomics-guided treatment recommendations </h3> <p> Specific somatic alterations were matched to potential therapeutic options (within the study pharmacopeia) using custom drug rules, as previously described [ <a aria-describedby=\"pone.0179170.ref018\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref018\"> 18 </a> , <a aria-describedby=\"pone.0179170.ref019\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref019\"> 19 </a> ]. The pharmacopeia for this study consisted of FDA-approved oncology drugs, including on-label and off-label use of these agents. An interpretive genomic report outlining the somatic alterations with potential therapeutic implications, as well as alterations in genes implicated in cancer, was generated for each patient. A molecular tumor board, consisting of the treating oncologist, clinical investigator, genomics experts and/or biology experts, reviewed the interpretive genomics report and discussed potential treatment options. A treatment strategy was recommended, and, if agreed upon by the treating oncologist and patient, the recommendation was pursued for treatment. If the prescription was denied by the insurer, appeal to insurance was made followed by request for drug from the manufacturer using a patient assistance or drug acquisition program. </p> </section> <section id=\"sec010\"> <h3 class=\"pmc_sec_title\"> Study endpoints </h3> <p> The primary objective of this study was to launch a pilot study enrolling 12 eligible patients with advanced SCLC and to obtain the necessary tumor biopsies to yield sufficient DNA and RNA for genome-wide interrogation. The secondary objective was to provide a new clinical paradigm in the treatment of SCLC such that each individual patient would be treated with a single-agent or combination therapy of commercially available agents that relates to particular target(s) that have been identified via NGS. </p> </section> </section> <section id=\"sec011\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"sec011-anchor\"> </a> Results </h2> <section id=\"sec012\"> <h3 class=\"pmc_sec_title\"> Patient characteristics </h3> <p> All patients were seen and evaluated for inclusion in this study between October 2014 and April 2016 at a single center. </p> <p> <a class=\"usa-link\" href=\"#pone.0179170.g001\"> Fig 1 </a> details the Consolidated Standards of Reporting Trials (CONSORT) diagram demonstrating the flow of the 13 patients who consented and were evaluated for the study ( <a class=\"usa-link\" href=\"#pone.0179170.s003\"> S2 File </a> ). There was one screen failure due to anticipated inadequate sample yield because of tumor location. The cohort included 10 women, median age was 56.5 years, and included 3 never smokers. All patients received prior platinum-based chemotherapy and were receiving &gt;1 <sup> st </sup> line systemic treatment while awaiting NGS results. </p> <figure class=\"fig xbox font-sm\" id=\"pone.0179170.g001\"> <h4 class=\"obj_head\"> Fig 1. CONSORT diagram. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=5460863_pone.0179170.g001.jpg\" target=\"_blank\"> <img alt=\"Fig 1\" class=\"graphic zoom-in\" height=\"527\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6b7/5460863/35a5b5236216/pone.0179170.g001.jpg\" width=\"625\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/pone.0179170.g001/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> Displays the flow of the 13 patients who consented and were evaluated for the study. There was one screen failure due to anticipated inadequate sample yield because of tumor location. </p> </figcaption> </figure> <p> For the 12 eligible patients with sufficient tumor tissue, we performed tumor/normal genome-wide exome sequencing to identify somatic alterations. Eleven patients had available tumor RNA that was successfully analyzed by RNA-sequencing. Sequencing metrics and summary statistics for each of the eligible patients are shown in <a class=\"usa-link\" href=\"#pone.0179170.t001\"> Table 1 </a> . </p> <section class=\"tw xbox font-sm\" id=\"pone.0179170.t001\"> <h4 class=\"obj_head\"> Table 1. NGS sequencing metrics. </h4> <div class=\"tbl-box p\" tabindex=\"0\"> <table class=\"content\" frame=\"hsides\" rules=\"groups\"> <colgroup span=\"1\"> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> </colgroup> <thead> <tr> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Patients </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Tumor Exome Aligned Reads (millions) </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Tumor Exome Average Target Coverage </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Tumor Exome &gt;100X Target Coverage </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Normal Exome Aligned Reads (millions) </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Normal Exome Average Target Coverage </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Tumor RNA Aligned Reads (millions) </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Tumor RNA % mRNA Bases <a class=\"usa-link\" href=\"#t001fn002\"> <sup> a </sup> </a> </th> </tr> </thead> <tbody> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC001 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 360 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 310X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 92% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 166 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 158X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 325 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 87% </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC002 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 235 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 222X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 82% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 116 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 118X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 170 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 87% </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC003 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 361 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 337X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 92% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 160 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 156X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 240 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 91% </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC004 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 406 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 386X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 93% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 164 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 161X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 282 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 91% </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC006 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 436 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 423X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 94% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 199 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 200X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 319 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 90% </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC007 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 481 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 505X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 94% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 238 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 267X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 218 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 88% </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC008 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 458 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 460X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 93% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 216 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 228X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 202 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 89% </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC009 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 557 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 560X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 96% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 243 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 244X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 172 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 90% </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC010 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 301 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 326X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 90% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 155 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 173X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 377 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 88% </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC011 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 526 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 540X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 95% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 187 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 210X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 178 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 91% </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC012 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 514 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 534X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 94% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 247 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 270X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> N/A </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> N/A </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC013 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 449 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 441X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 95% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 202 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 222X </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 250 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 92% </td> </tr> </tbody> </table> </div> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"table/pone.0179170.t001/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <div class=\"tw-foot p\"> <div class=\"fn\" id=\"t001fn001\"> <p> N/A, not available. </p> </div> <div class=\"fn\" id=\"t001fn002\"> <p> <sup> a </sup> Percent of aligned bases that map to coding regions and UTRs of mRNA transcripts. </p> </div> </div> </section> <p> Tumor content averaged &gt;80% and ranged from 20\u2013100% based on pathology review. The minimum tumor content for successful NGS was 20%. The median turnaround time from sample collection to report was 15 days (range 11\u201317). The median turnaround time from sample collection to a genomics-based treatment recommendation by the molecular tumor board was 27 days (range 21\u201339). The median time to initiation of NGS guided treatment for the three patients that received NGS guided therapy after the molecular tumor board recommendation was 32 days (range 30\u201359). For the six patients that did not receive NGS guided therapy, the median time to clinical deterioration from the molecular tumor board recommendation was 10 days (range 0\u201345) ( <a class=\"usa-link\" href=\"#pone.0179170.t002\"> Table 2 </a> ). </p> <section class=\"tw xbox font-sm\" id=\"pone.0179170.t002\"> <h4 class=\"obj_head\"> Table 2. NGS turnaround time metrics. </h4> <div class=\"tbl-box p\" tabindex=\"0\"> <table class=\"content\" frame=\"hsides\" rules=\"groups\"> <colgroup span=\"1\"> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> </colgroup> <thead> <tr> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Patient Number </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Tumor content by Pathology </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Days from samples received to date of report </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Days from samples received to molecular tumor board recommendation </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Patient received NGS guided treatment? </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Days from disease progression (PD) on previous therapy to start on NGS guided treatment or clinical deterioration </th> </tr> </thead> <tbody> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0001 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 20% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 16 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 21 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Yes </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 59 </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0002 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 99% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 11 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 24 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> No </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 8 </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0003 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 75% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 17 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 27 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> No </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 11 </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0004 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 50% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 15 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 25 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Yes </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Prior to NGS result becoming available </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0006 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 99% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 15 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 27 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> No </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 0 </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0007 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 95% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 17 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 24 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Yes </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 30 </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0008 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 80% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 16 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 28 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Yes </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Prior to NGS result becoming available </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0009 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 80% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 14 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 26 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> No </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 45 </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0010 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 100% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 14 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 34 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Yes </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 32 </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0011 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 98% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 14 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 24 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> No </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 0 </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0012 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 100% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 17 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 39 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> No </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 12 </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0013 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 98% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 15 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 32 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Yes </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Prior to NGS result becoming available </td> </tr> </tbody> </table> </div> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"table/pone.0179170.t002/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> </section> <p> Average Exome coverage was 420X (tumor), 201X (germline), with an average of 248 million aligned RNA reads generated for tumors. The number and type of genomic aberrations for each patient are depicted in <a class=\"usa-link\" href=\"#pone.0179170.g002\"> Fig 2 </a> . </p> <figure class=\"fig xbox font-sm\" id=\"pone.0179170.g002\"> <h4 class=\"obj_head\"> Fig 2. Genomic alteration overview. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=5460863_pone.0179170.g002.jpg\" target=\"_blank\"> <img alt=\"Fig 2\" class=\"graphic zoom-in\" height=\"579\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6b7/5460863/b5e29c83410f/pone.0179170.g002.jpg\" width=\"800\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/pone.0179170.g002/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> Summary of the number and types of somatic variants detected by tumor/normal genome-wide exome and tumor RNA-sequencing for each SCLC patient (n = 12). </p> </figcaption> </figure> <p> <a class=\"usa-link\" href=\"#pone.0179170.t003\"> Table 3 </a> lists the clinical characteristics for the 12 eligible patients who consented for this study, and <a class=\"usa-link\" href=\"#pone.0179170.g003\"> Fig 3 </a> summarizes the molecular findings. As expected, TP53 and RB1 were recurrently altered in this cohort, with mutations and/or copy number loss of these genes co-occurring in two-thirds (8 out of 12) of the tumors ( <a class=\"usa-link\" href=\"#pone.0179170.g003\"> Fig 3 </a> ). Potentially actionable alterations were observed in all patients, though few genes were recurrently altered in more than one patient. All patients had at least two clinically actionable targets identified (associated with a commercially-available, FDA-approved drug by predefined rules), with a median of three targets (range 2\u201311). <a class=\"usa-link\" href=\"#pone.0179170.s001\"> S1 Table </a> contains additional information on these potentially actionable genomic alterations. </p> <section class=\"tw xbox font-sm\" id=\"pone.0179170.t003\"> <h4 class=\"obj_head\"> Table 3. Clinical characteristics for the eligible patients. </h4> <div class=\"tbl-box p\" tabindex=\"0\"> <table class=\"content\" frame=\"hsides\" rules=\"groups\"> <colgroup span=\"1\"> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> </colgroup> <thead> <tr> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Patient </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Age at entry </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Gender </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Ethnicity </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Cig hx </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> KPS at entry </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Prior treatment </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Platinum sensitive, resistant, or refractory </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Prior brain mets? </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Biopsy site </th> </tr> </thead> <tbody> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0001 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 74 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> F </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Caucasian </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Yes </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 90% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Carbo/etop </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Resistant </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> No </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Liver mass </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0002 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 56 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> F </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Caucasian </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Yes </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 90% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Cis/etop </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Sensitive </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> No </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Liver mass </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0003 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 68 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> M </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Caucasian </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Yes </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 80% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Irino </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Refractory </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> No </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Right lung mass </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0004 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 57 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> M </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Caucasian </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Yes </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 90% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Carbo/etop </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Resistant </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> No </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Adrenal mass </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0006 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 51 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> F </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Caucasian </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Yes </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 80% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Cis/etop </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Refractory </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> No </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Cervical lymph node </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0007 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 43 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> F </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Native American </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> No </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 90% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Cis/etop/XRT/topo </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Sensitive </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> No </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Right lower lung mass </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0008 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 60 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> M </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Caucasian </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Yes </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 90% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Carbo/etop </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Resistant </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> No </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Left supra lymph node </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0009 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 57 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> F </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Caucasian </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> No </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 90% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Carbo/etop, /topo </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Refractory </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Yes </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Liver mass </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0010 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 66 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> F </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Caucasian/Hispanic </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Yes </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 90% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Carbo/etop, /topo, pacli </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Resistant </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> No </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Left lower lung mass </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0011 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 54 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> F </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Caucasian </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Yes </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 70% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Cis/etop </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Refractory </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Yes </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Left cervical jugular lymph node </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0012 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 55 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> F </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Caucasian </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> No </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 80% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Cis/etop/XRT/topo </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Sensitive </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> No </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Right preauricular mass </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0013 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 54 </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> F </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Caucasian </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Yes </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> 80% </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Cis/etop/XRT </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Refractory </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Yes </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Liver mass </td> </tr> </tbody> </table> </div> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"table/pone.0179170.t003/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <div class=\"tw-foot p\"> <div class=\"fn\" id=\"t003fn001\"> <p> M, male; F, female; Cig hx, smoking history; KPS, Karnofsky Performance Status; carbo, carboplatin; etop, etoposide; cis, cisplatin; irino, irinotecan; XRT, radiation; topo, topotecan; pacli, paclitaxel; mets, metastases; supra, supraclavicular. </p> </div> </div> </section> <figure class=\"fig xbox font-sm\" id=\"pone.0179170.g003\"> <h4 class=\"obj_head\"> Fig 3. Summary of genomic alterations. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=5460863_pone.0179170.g003.jpg\" target=\"_blank\"> <img alt=\"Fig 3\" class=\"graphic zoom-in\" height=\"236\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6b7/5460863/f3e4059e8fa7/pone.0179170.g003.jpg\" width=\"800\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/pone.0179170.g003/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> Frequency and spectrum of selected alterations detected in advanced small cell lung carcinoma cases (n = 12). Genes previously reported to be recurrently altered in SCLC are presented, along with alterations deemed potentially therapeutically actionable. </p> </figcaption> </figure> <p> Six (50%) patients received treatment identified by NGS ( <a class=\"usa-link\" href=\"#pone.0179170.t004\"> Table 4 </a> ). For three of these patients, their treatment linked to NGS was already initiated prior to the NGS report becoming available. Of these, two had partial responses by RECIST 1.1 &gt;10 months on a clinical trial involving PD-1 inhibitor + irinotecan (indicated by <em> MLH1 </em> molecular alterations) (Representative example in <a class=\"usa-link\" href=\"#pone.0179170.g004\"> Fig 4 </a> ). Three had disease progression (PD) as best overall response: one on PD-1 inhibitor (indicated by a <em> PMS2 </em> mutation), one on dasatinib (indicated by KIT overexpression), and one on temozolomide (indicated by <em> LIG4 </em> copy number loss). The remaining six evaluable patients had clinical deterioration before NGS recommended therapy could be initiated. </p> <section class=\"tw xbox font-sm\" id=\"pone.0179170.t004\"> <h4 class=\"obj_head\"> Table 4. Summary of treatment received and response. </h4> <div class=\"tbl-box p\" tabindex=\"0\"> <table class=\"content\" frame=\"hsides\" rules=\"groups\"> <colgroup span=\"1\"> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> </colgroup> <thead> <tr> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Patient </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Recommended therapy received </th> <th align=\"center\" colspan=\"1\" rowspan=\"1\"> Best response </th> </tr> </thead> <tbody> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0001 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Dasatinib </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> PD </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0002 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> None </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> na </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0003 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> None </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> na </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0004 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Irinotecan + PD1 <a class=\"usa-link\" href=\"#t004fn002\"> <sup> a </sup> </a> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> PR </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0006 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> None </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> na </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0007 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Irinotecan </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> SD </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0008 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Irinotecan + PD1 <a class=\"usa-link\" href=\"#t004fn002\"> <sup> a </sup> </a> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> PR </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0009 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> None </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> na </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0010 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Temozolomide </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> PD </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0011 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> None </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> na </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0012 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> None </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> na </td> </tr> <tr> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> <strong> SCLC0013 </strong> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> Irinotecan + PD1 <a class=\"usa-link\" href=\"#t004fn002\"> <sup> a </sup> </a> </td> <td align=\"center\" colspan=\"1\" rowspan=\"1\"> PD </td> </tr> </tbody> </table> </div> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"table/pone.0179170.t004/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <div class=\"tw-foot p\"> <div class=\"fn\" id=\"t004fn001\"> <p> PD, disease progression; SD, stable disease; PR, partial response; na, not applicable. </p> </div> <div class=\"fn\" id=\"t004fn002\"> <p> <sup> a </sup> Treatment started prior to genomic results being available. </p> </div> </div> </section> <figure class=\"fig xbox font-sm\" id=\"pone.0179170.g004\"> <h4 class=\"obj_head\"> Fig 4. Representative example. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=5460863_pone.0179170.g004.jpg\" target=\"_blank\"> <img alt=\"Fig 4\" class=\"graphic zoom-in\" height=\"526\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6b7/5460863/a6b42c56e676/pone.0179170.g004.jpg\" width=\"746\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/pone.0179170.g004/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> (A) Circos plot for SCLC0008, with potentially actionable alterations listed in red font. (B) Summary of the type and number of genomic aberrations detected for SCLC0008. Level 1 corresponds to alterations viewed as potentially clinically actionable. (C) A representative baseline radiographic image (top image) and a response evaluation scan at 11 months (bottom image) for SCLC0008, with the red circle surrounding tumor burden in the retroperitoneum and left adrenal gland. The overall tumor burden decreased from 10.8 cm to 2.3 cm, with CEA tumor marker decreasing from 94.8 to 7.8. </p> </figcaption> </figure> <p> Three of the twelve patients were treated with a PD-1 inhibitor in combination with irinotecan as part of a separate, ongoing clinical trial ( <a class=\"usa-link\" href=\"https://clinicaltrials.gov/ct2/show/NCT02331251\" rel=\"noopener noreferrer\" target=\"_blank\"> NCT02331251 </a> ). Two of the three demonstrated partial responses by RECIST 1.1 criteria, while the other patient had PD as a best response. In the two patients with partial responses (SCLC0004, SCLC0008), exome-sequencing identified 1031 and 585 somatic missense mutations ( <a class=\"usa-link\" href=\"#pone.0179170.g002\"> Fig 2 </a> ) as well as molecular alterations in <em> MLH1 </em> in both tumors ( <a class=\"usa-link\" href=\"#pone.0179170.g003\"> Fig 3 </a> ). These 2 patients had the highest mutational burdens across the cohort (average mutation count: 273). The patient that progressed on PD-1 + irinotecan (SCLC0013) harbored 83 missense mutations, and was linked to PD-1 by an alteration in <em> PMS2 </em> . </p> </section> </section> <section id=\"sec013\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"sec013-anchor\"> </a> Discussion </h2> <p> This pilot study aimed to demonstrate feasibility of the employment of NGS-guided treatment in advanced SCLC, an effort to bring us closer to precision medicine for SCLC. Results generated from this work use a novel approach to identify and characterize new contexts of vulnerability for both current therapies and agents in development, thus enabling accelerated clinical implementation. Completion of the work proposed here will generate additional support for future precision medicine studies in SCLC to the benefit of more patients with this devastating cancer. We will develop and validate this approach to include a flexible cadre of cutting-edge genomic technologies that will also serve to inform precision medicine for other cancer types, leveraging the current study design as a template. </p> <p> Conducting novel pilot studies using fresh tumor tissue from advanced cancer patients is not a new endeavor for our group. The SCRI-CA-001 \u201cBisgrove\u201d Trial was a prospective, open-labeled, nine-center study designed to determine whether molecular profiling tumors from patients with advanced, previously treated cancer could provide any benefit to patients [ <a aria-describedby=\"pone.0179170.ref020\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref020\"> 20 </a> ]. To be eligible, patients must have had 2\u20134 prior chemotherapies or hormonal or biologic regimens for their advanced disease, measurable or evaluable refractory disease, and clear documentation of the time between initiation of treatment and documented progression on the last treatment prior to study entry. Patients with all histologic types of malignancy were allowed on study. The patients were treated based on the results generated in the molecular profiling. The primary objective was to determine the growth modulation index (GMI) of treatment regimens selected by profiling of tumor biopsies. Molecular profiling was deemed of clinical benefit for the individual patient who had a GMI ratio &gt;1.3. This was the first published study utilizing molecular profiling to find potential target and select treatments accordingly. Eighty-six patients were profiled with a molecular target identified in 84 (98%). Sixty-six patients were treated according to the profiling results of which 18/66 (27%) had a PFS ratio advantage \u2265 1.3 [ <a aria-describedby=\"pone.0179170.ref020\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref020\"> 20 </a> ]. There were also one complete and five partial responses, as well as, 14 patients without progression at 4 months. In most patients, successful tumor profiling supported the indication of a new treatment not contemplated initially by the physician. </p> <p> The results from the NFCR trial demonstrate that we have the ability and experience to conduct not only WGS in advanced cancer patients, but also whole-transcriptome sequencing (WTS) with integrated DNA and RNA analyses [ <a aria-describedby=\"pone.0179170.ref016\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref016\"> 16 </a> ]. This advancement demonstrates improvement in our next generation sequencing pipeline, which now also involves tumor DNA and RNA isolation within our in-house CLIA-certified diagnostic laboratory, improving the turn-around time from analyte extraction and quality control to interpreted sequence data. As the reagent chemistry for sequencing has improved, we can now perform GWS with sufficient coverage even when the tumor comprises only 20% of the total sample volume. With these collective resources, we are poised to apply our state-of-the-art technologies to patients with advanced SCLC, as well as other advanced tumor types. </p> <p> A takeaway lesson from both the Bisgrove and NFCR studies was the importance of turnaround time of results to be able to act upon the NGS guided recommendation for patients with advanced/metastatic and recently progressed disease. To that end, all patients in this trial were offered next line therapy while whole exome and transcriptome sequencing was being performed to allow for sufficient time to get to the recommendations when they would be needed. Somewhat surprising is that despite this strategy, half of the patients still had clinical deterioration making them ineligible for NGS guided therapy. Getting a NGS report turnaround sooner would not have made a difference clinically for these six patients. One possible solution for future studies involving SCLC patients, would be earlier access to NGS guided therapy. With continuing improvements in pricing, employing NGS during first-line therapy coupled with a proactive approach to securing coverage/approval for NGS guided therapy or the identification of an appropriate clinical trial based on the NGS findings, may allow for a higher percentage of patients getting NGS guided therapy. Only with a sufficient fraction of the study population receiving NGS guided therapy, can the potential value of its application be measured. </p> <p> The success of immune checkpoint inhibitors has led to use of these therapeutics across a wide range of tumor types. Blockade of CTLA4 and/or PD-1/PD-L1 have shown clinical successes in melanoma, lung cancer, and other tumor types [ <a aria-describedby=\"pone.0179170.ref021\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref021\"> 21 </a> , <a aria-describedby=\"pone.0179170.ref022\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref022\"> 22 </a> ]. In SCLC, a number of completed or ongoing clinical trials (reviewed in [ <a aria-describedby=\"pone.0179170.ref005\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref005\"> 5 </a> , <a aria-describedby=\"pone.0179170.ref013\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref013\"> 13 </a> ]) have demonstrated clinical efficacy with these immune-based therapies alone or in combination with chemotherapy. A phase I/II study (CheckMate 032) employing nivolumab with or without ipilimumab in recurrent SCLC demonstrated an overall response rate of 10% or 19\u201323%, respectively [ <a aria-describedby=\"pone.0179170.ref015\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref015\"> 15 </a> ]. There was no correlation between PD-L1 expression and response. In another phase 1b trial, PD-L1-positive patients with extensive stage SCLC were treated with pembrolizumab, and displayed an overall response rate of 35%, although again with no significant relationship between level of PD-L1 expression and response [ <a aria-describedby=\"pone.0179170.ref014\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref014\"> 14 </a> ]. Thus, while success of PD-1 inhibitors in SCLC has been demonstrated, markers of response/resistance are lacking. In this study, two of three patients had partial responses on PD-1 inhibition in combination with irinotecan. It should be emphasized that their treatment was already initiated prior to the NGS report becoming available. The two responders had molecular alterations in <em> MLH1 </em> and the highest frequencies of missense mutations. The patient with PD had an alteration in <em> PMS2 </em> , and a low mutational burden. Previous work has shown correlations between immune therapy response and mutational burden, including a molecular smoking signature [ <a aria-describedby=\"pone.0179170.ref023\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref023\"> 23 </a> , <a aria-describedby=\"pone.0179170.ref024\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref024\"> 24 </a> ]. Molecular alterations in <em> MLH1 </em> also correlated with response to PD-1 inhibitors or PD-L1 protein staining [ <a aria-describedby=\"pone.0179170.ref025\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref025\"> 25 </a> , <a aria-describedby=\"pone.0179170.ref026\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pone.0179170.ref026\"> 26 </a> ]. Our data suggest that a combination of molecular alteration and mutational burden may better predict response to PD-1 inhibition, molecular outcomes afforded by deeper sequencing techniques. Future work will explore these combinational biomarkers to determine immune therapy response. </p> <p> In conclusion, this pilot trial successfully recruited the goal of 12 patients with SCLC that progressed on frontline chemotherapeutic options. Next-generation sequencing revealed potential therapeutic targets in all 12 patients. SCLC after first-line therapy tends to have more rapid progression and deterioration making NGS application for systemic therapy challenging. Two patients demonstrated partial responses on a combinational regimen of an immune checkpoint inhibitor + irinotecan, a regimen post-hoc revealed by NGS and suggested by mismatch repair gene alterations. Earlier access to NGS guided therapy, along with a better understanding of those SCLC patients likely to respond to immune-based therapies should help to extend survival in these cases with poor outcomes. </p> </section> <section id=\"sec014\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"sec014-anchor\"> </a> Supporting information </h2> <section class=\"sm xbox font-sm\" id=\"pone.0179170.s001\"> <div class=\"caption p\"> <span> S1 Table. Summary of potentially actionable genomic alterations. </span> <p> Detailed information on potentially therapeutically actionable alterations identified in 12 SCLC tumors. </p> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/5460863/bin/pone.0179170.s001.xlsx\"> Click here for additional data file. </a> <sup> (45.6KB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pone.0179170.s002\"> <div class=\"caption p\"> <span> S1 File. Protocol. </span> <p> The protocol for this pilot study. </p> <p> (PDF) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/5460863/bin/pone.0179170.s002.pdf\"> Click here for additional data file. </a> <sup> (491.3KB, pdf) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pone.0179170.s003\"> <div class=\"caption p\"> <span> S2 File. TREND checklist. </span> <p> The completed TREND checklist submitted for this manuscript. </p> <p> (PDF) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/5460863/bin/pone.0179170.s003.pdf\"> Click here for additional data file. </a> <sup> (98.1KB, pdf) </sup> </div> </div> </section> </section> <section class=\"ack\" id=\"ack1\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"ack1-anchor\"> </a> Acknowledgments </h2> <p> We are grateful to the patients and clinical staff for participating in this trial. We also thank the clinical research coordinators, Carly Benford and Callie Sinclair, for their assistance on this study. </p> </section> <section id=\"notes1\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"notes1-anchor\"> </a> Data Availability </h2> <p> All NGS files are available from dbGaP under accession, phs001366.v1.p1 ( <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001366.v1.p1\" rel=\"noopener noreferrer\" target=\"_blank\"> https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001366.v1.p1 </a> ). </p> </section> <section id=\"funding-statement1\" lang=\"en\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"funding-statement1-anchor\"> </a> Funding Statement </h2> <p> This work was supported by Stand Up to Cancer (SU2C). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. One or more of the authors received consulting fees from a commercial company: Blend Therapeutics, Pharmatech, Viomics, and Paradigm; speakers' bureau: Medscape, Merck, Novartis; Travel: NantWorks, Arbutus Biopharma and GE Global Research, Dell Inc., and Strategia Therapeutics, Inc. These funders provided support in the form of salaries for authors [GJW, TGW, SAB], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the \u2018author contributions\u2019 section. </p> </section> <section class=\"ref-list\" id=\"ref-list1\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"ref-list1-anchor\"> </a> References </h2> <section id=\"ref-list1_sec2\"> <ul class=\"ref-list font-sm\"> <li id=\"pone.0179170.ref001\"> <span class=\"label\"> 1. </span> <cite> Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7\u201330. 10.3322/caac.21387 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.3322/caac.21387\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/28055103/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=CA%20Cancer%20J%20Clin&amp;title=Cancer%20Statistics,%202017&amp;author=RL%20Siegel&amp;author=KD%20Miller&amp;author=A%20Jemal&amp;volume=67&amp;issue=1&amp;publication_year=2017&amp;pages=7-30&amp;pmid=28055103&amp;doi=10.3322/caac.21387&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref002\"> <span class=\"label\"> 2. </span> <cite> Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539\u201344. 10.1200/JCO.2005.04.4859 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1200/JCO.2005.04.4859\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/17008692/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Changing%20epidemiology%20of%20small-cell%20lung%20cancer%20in%20the%20United%20States%20over%20the%20last%2030%20years:%20analysis%20of%20the%20surveillance,%20epidemiologic,%20and%20end%20results%20database&amp;author=R%20Govindan&amp;author=N%20Page&amp;author=D%20Morgensztern&amp;author=W%20Read&amp;author=R%20Tierney&amp;volume=24&amp;issue=28&amp;publication_year=2006&amp;pages=4539-44&amp;pmid=17008692&amp;doi=10.1200/JCO.2005.04.4859&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref003\"> <span class=\"label\"> 3. </span> <cite> Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, et al. Small cell lung cancer. J Natl Compr Canc Netw. 2013;11(1):78\u201398. . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.6004/jnccn.2013.0011\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3715060/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/23307984/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J%20Natl%20Compr%20Canc%20Netw&amp;title=Small%20cell%20lung%20cancer&amp;author=GP%20Kalemkerian&amp;author=W%20Akerley&amp;author=P%20Bogner&amp;author=H%20Borghaei&amp;author=LQ%20Chow&amp;volume=11&amp;issue=1&amp;publication_year=2013&amp;pages=78-98&amp;pmid=23307984&amp;doi=10.6004/jnccn.2013.0011&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref004\"> <span class=\"label\"> 4. </span> <cite> von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658\u201367. 10.1200/JCO.1999.17.2.658 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1200/JCO.1999.17.2.658\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/10080612/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Topotecan%20versus%20cyclophosphamide,%20doxorubicin,%20and%20vincristine%20for%20the%20treatment%20of%20recurrent%20small-cell%20lung%20cancer&amp;author=J%20von%20Pawel&amp;author=JH%20Schiller&amp;author=FA%20Shepherd&amp;author=SZ%20Fields&amp;author=JP%20Kleisbauer&amp;volume=17&amp;issue=2&amp;publication_year=1999&amp;pages=658-67&amp;pmid=10080612&amp;doi=10.1200/JCO.1999.17.2.658&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref005\"> <span class=\"label\"> 5. </span> <cite> Kalemkerian GP. Small Cell Lung Cancer. Semin Respir Crit Care Med. 2016;37(5):783\u201396. 10.1055/s-0036-1592116 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1055/s-0036-1592116\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/27732999/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Semin%20Respir%20Crit%20Care%20Med&amp;title=Small%20Cell%20Lung%20Cancer&amp;author=GP%20Kalemkerian&amp;volume=37&amp;issue=5&amp;publication_year=2016&amp;pages=783-96&amp;pmid=27732999&amp;doi=10.1055/s-0036-1592116&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref006\"> <span class=\"label\"> 6. </span> <cite> Tiseo M, Ardizzoni A. Current status of second-line treatment and novel therapies for small cell lung cancer. J Thorac Oncol. 2007;2(8):764\u201372. 10.1097/JTO.0b013e3180986262 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1097/JTO.0b013e3180986262\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/17762346/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J%20Thorac%20Oncol&amp;title=Current%20status%20of%20second-line%20treatment%20and%20novel%20therapies%20for%20small%20cell%20lung%20cancer&amp;author=M%20Tiseo&amp;author=A%20Ardizzoni&amp;volume=2&amp;issue=8&amp;publication_year=2007&amp;pages=764-72&amp;pmid=17762346&amp;doi=10.1097/JTO.0b013e3180986262&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref007\"> <span class=\"label\"> 7. </span> <cite> von Pawel J, Jotte R, Spigel DR, O'Brien ME, Socinski MA, Mezger J, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32(35):4012\u20139. 10.1200/JCO.2013.54.5392 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1200/JCO.2013.54.5392\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/25385727/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Randomized%20phase%20III%20trial%20of%20amrubicin%20versus%20topotecan%20as%20second-line%20treatment%20for%20patients%20with%20small-cell%20lung%20cancer&amp;author=J%20von%20Pawel&amp;author=R%20Jotte&amp;author=DR%20Spigel&amp;author=ME%20O'Brien&amp;author=MA%20Socinski&amp;volume=32&amp;issue=35&amp;publication_year=2014&amp;pages=4012-9&amp;pmid=25385727&amp;doi=10.1200/JCO.2013.54.5392&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref008\"> <span class=\"label\"> 8. </span> <cite> Lohinai Z, Dome P, Szilagyi Z, Ostoros G, Moldvay J, Hegedus B, et al. From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC). PLoS One. 2016;11(1):e0144797 10.1371/journal.pone.0144797 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1371/journal.pone.0144797\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4703211/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26735301/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=PLoS%20One&amp;title=From%20Bench%20to%20Bedside:%20Attempt%20to%20Evaluate%20Repositioning%20of%20Drugs%20in%20the%20Treatment%20of%20Metastatic%20Small%20Cell%20Lung%20Cancer%20(SCLC)&amp;author=Z%20Lohinai&amp;author=P%20Dome&amp;author=Z%20Szilagyi&amp;author=G%20Ostoros&amp;author=J%20Moldvay&amp;volume=11&amp;issue=1&amp;publication_year=2016&amp;pages=e0144797&amp;pmid=26735301&amp;doi=10.1371/journal.pone.0144797&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref009\"> <span class=\"label\"> 9. </span> <cite> Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543\u201350. 10.1038/nature13385 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nature13385\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4231481/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/25079552/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Comprehensive%20molecular%20profiling%20of%20lung%20adenocarcinoma&amp;volume=511&amp;issue=7511&amp;publication_year=2014&amp;pages=543-50&amp;pmid=25079552&amp;doi=10.1038/nature13385&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref010\"> <span class=\"label\"> 10. </span> <cite> George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524(7563):47\u201353. 10.1038/nature14664 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nature14664\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4861069/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26168399/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Comprehensive%20genomic%20profiles%20of%20small%20cell%20lung%20cancer&amp;author=J%20George&amp;author=JS%20Lim&amp;author=SJ%20Jang&amp;author=Y%20Cun&amp;author=L%20Ozretic&amp;volume=524&amp;issue=7563&amp;publication_year=2015&amp;pages=47-53&amp;pmid=26168399&amp;doi=10.1038/nature14664&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref011\"> <span class=\"label\"> 11. </span> <cite> Simbolo M, Mafficini A, Sikora KO, Fassan M, Barbi S, Corbo V, et al. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. J Pathol. 2017;241(4):488\u2013500. 10.1002/path.4853 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1002/path.4853\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC5324596/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/27873319/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J%20Pathol&amp;title=Lung%20neuroendocrine%20tumours:%20deep%20sequencing%20of%20the%20four%20World%20Health%20Organization%20histotypes%20reveals%20chromatin-remodelling%20genes%20as%20major%20players%20and%20a%20prognostic%20role%20for%20TERT,%20RB1,%20MEN1%20and%20KMT2D&amp;author=M%20Simbolo&amp;author=A%20Mafficini&amp;author=KO%20Sikora&amp;author=M%20Fassan&amp;author=S%20Barbi&amp;volume=241&amp;issue=4&amp;publication_year=2017&amp;pages=488-500&amp;pmid=27873319&amp;doi=10.1002/path.4853&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref012\"> <span class=\"label\"> 12. </span> <cite> Karachaliou N, Pilotto S, Lazzari C, Bria E, de Marinis F, Rosell R. Cellular and molecular biology of small cell lung cancer: an overview. Transl Lung Cancer Res. 2016;5(1):2\u201315. 10.3978/j.issn.2218-6751.2016.01.02 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.3978/j.issn.2218-6751.2016.01.02\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4758976/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26958489/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Transl%20Lung%20Cancer%20Res&amp;title=Cellular%20and%20molecular%20biology%20of%20small%20cell%20lung%20cancer:%20an%20overview&amp;author=N%20Karachaliou&amp;author=S%20Pilotto&amp;author=C%20Lazzari&amp;author=E%20Bria&amp;author=F%20de%20Marinis&amp;volume=5&amp;issue=1&amp;publication_year=2016&amp;pages=2-15&amp;pmid=26958489&amp;doi=10.3978/j.issn.2218-6751.2016.01.02&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref013\"> <span class=\"label\"> 13. </span> <cite> Mamdani H, Induru R, Jalal SI. Novel therapies in small cell lung cancer. Transl Lung Cancer Res. 2015;4(5):533\u201344. 10.3978/j.issn.2218-6751.2015.07.20 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.3978/j.issn.2218-6751.2015.07.20\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4630526/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26629422/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Transl%20Lung%20Cancer%20Res&amp;title=Novel%20therapies%20in%20small%20cell%20lung%20cancer&amp;author=H%20Mamdani&amp;author=R%20Induru&amp;author=SI%20Jalal&amp;volume=4&amp;issue=5&amp;publication_year=2015&amp;pages=533-44&amp;pmid=26629422&amp;doi=10.3978/j.issn.2218-6751.2015.07.20&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref014\"> <span class=\"label\"> 14. </span> <cite> Paglialunga L, Salih Z, Ricciuti B, Califano R. Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? ESMO Open. 2016;1(4):e000022 10.1136/esmoopen-2015-000022 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1136/esmoopen-2015-000022\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC5070242/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/27843619/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=ESMO%20Open&amp;title=Immune%20checkpoint%20blockade%20in%20small%20cell%20lung%20cancer:%20is%20there%20a%20light%20at%20the%20end%20of%20the%20tunnel?&amp;author=L%20Paglialunga&amp;author=Z%20Salih&amp;author=B%20Ricciuti&amp;author=R%20Califano&amp;volume=1&amp;issue=4&amp;publication_year=2016&amp;pages=e000022&amp;pmid=27843619&amp;doi=10.1136/esmoopen-2015-000022&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref015\"> <span class=\"label\"> 15. </span> <cite> Antonia SJ, Lopez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(7):883\u201395. 10.1016/S1470-2045(16)30098-5 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/S1470-2045(16)30098-5\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/27269741/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Nivolumab%20alone%20and%20nivolumab%20plus%20ipilimumab%20in%20recurrent%20small-cell%20lung%20cancer%20(CheckMate%20032):%20a%20multicentre,%20open-label,%20phase%201/2%20trial&amp;author=SJ%20Antonia&amp;author=JA%20Lopez-Martin&amp;author=J%20Bendell&amp;author=PA%20Ott&amp;author=M%20Taylor&amp;volume=17&amp;issue=7&amp;publication_year=2016&amp;pages=883-95&amp;pmid=27269741&amp;doi=10.1016/S1470-2045(16)30098-5&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref016\"> <span class=\"label\"> 16. </span> <cite> Weiss GJ, Liang WS, Demeure MJ, Kiefer JA, Hostetter G, Izatt T, et al. A pilot study using next-generation sequencing in advanced cancers: feasibility and challenges. PLoS One. 2013;8(10):e76438 10.1371/journal.pone.0076438 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1371/journal.pone.0076438\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3813699/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/24204627/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=PLoS%20One&amp;title=A%20pilot%20study%20using%20next-generation%20sequencing%20in%20advanced%20cancers:%20feasibility%20and%20challenges&amp;author=GJ%20Weiss&amp;author=WS%20Liang&amp;author=MJ%20Demeure&amp;author=JA%20Kiefer&amp;author=G%20Hostetter&amp;volume=8&amp;issue=10&amp;publication_year=2013&amp;pages=e76438&amp;pmid=24204627&amp;doi=10.1371/journal.pone.0076438&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref017\"> <span class=\"label\"> 17. </span> <cite> Liang WS, Hendricks W, Kiefer J, Schmidt J, Sekar S, Carpten J, et al. Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma. Genome Res. 2017;27(4):524\u201332. 10.1101/gr.213348.116 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1101/gr.213348.116\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC5378171/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/28373299/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Genome%20Res&amp;title=Integrated%20genomic%20analyses%20reveal%20frequent%20TERT%20aberrations%20in%20acral%20melanoma&amp;author=WS%20Liang&amp;author=W%20Hendricks&amp;author=J%20Kiefer&amp;author=J%20Schmidt&amp;author=S%20Sekar&amp;volume=27&amp;issue=4&amp;publication_year=2017&amp;pages=524-32&amp;pmid=28373299&amp;doi=10.1101/gr.213348.116&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref018\"> <span class=\"label\"> 18. </span> <cite> LoRusso PM, Boerner SA, Pilat MJ, Forman KM, Zuccaro CY, Kiefer JA, et al. Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. Mol Cancer Ther. 2015;14(8):1962\u201371. 10.1158/1535-7163.MCT-15-0153 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1158/1535-7163.MCT-15-0153\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC5560131/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26063764/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Mol%20Cancer%20Ther&amp;title=Pilot%20Trial%20of%20Selecting%20Molecularly%20Guided%20Therapy%20for%20Patients%20with%20Non-V600%20BRAF-Mutant%20Metastatic%20Melanoma:%20Experience%20of%20the%20SU2C/MRA%20Melanoma%20Dream%20Team&amp;author=PM%20LoRusso&amp;author=SA%20Boerner&amp;author=MJ%20Pilat&amp;author=KM%20Forman&amp;author=CY%20Zuccaro&amp;volume=14&amp;issue=8&amp;publication_year=2015&amp;pages=1962-71&amp;pmid=26063764&amp;doi=10.1158/1535-7163.MCT-15-0153&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref019\"> <span class=\"label\"> 19. </span> <cite> Nasser S, Kurdolgu AA, Izatt T, Aldrich J, Russell ML, Christoforides A, et al. An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine. Pac Symp Biocomput. 2015:56\u201367. . </cite> [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/25592568/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Pac%20Symp%20Biocomput&amp;title=An%20integrated%20framework%20for%20reporting%20clinically%20relevant%20biomarkers%20from%20paired%20tumor/normal%20genomic%20and%20transcriptomic%20sequencing%20data%20in%20support%20of%20clinical%20trials%20in%20personalized%20medicine&amp;author=S%20Nasser&amp;author=AA%20Kurdolgu&amp;author=T%20Izatt&amp;author=J%20Aldrich&amp;author=ML%20Russell&amp;publication_year=2015&amp;pages=56-67&amp;pmid=25592568&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref020\"> <span class=\"label\"> 20. </span> <cite> Von Hoff DD, Stephenson JJ Jr., Rosen P, Loesch DM, Borad MJ, Anthony S, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010;28(33):4877\u201383. 10.1200/JCO.2009.26.5983 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1200/JCO.2009.26.5983\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/20921468/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Pilot%20study%20using%20molecular%20profiling%20of%20patients'%20tumors%20to%20find%20potential%20targets%20and%20select%20treatments%20for%20their%20refractory%20cancers&amp;author=DD%20Von%20Hoff&amp;author=JJ%20Stephenson&amp;author=P%20Rosen&amp;author=DM%20Loesch&amp;author=MJ%20Borad&amp;volume=28&amp;issue=33&amp;publication_year=2010&amp;pages=4877-83&amp;pmid=20921468&amp;doi=10.1200/JCO.2009.26.5983&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref021\"> <span class=\"label\"> 21. </span> <cite> Azoury SC, Straughan DM, Shukla V. Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety. Curr Cancer Drug Targets. 2015;15(6):452\u201362. . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.2174/156800961506150805145120\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26282545/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Curr%20Cancer%20Drug%20Targets&amp;title=Immune%20Checkpoint%20Inhibitors%20for%20Cancer%20Therapy:%20Clinical%20Efficacy%20and%20Safety&amp;author=SC%20Azoury&amp;author=DM%20Straughan&amp;author=V%20Shukla&amp;volume=15&amp;issue=6&amp;publication_year=2015&amp;pages=452-62&amp;pmid=26282545&amp;doi=10.2174/156800961506150805145120&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref022\"> <span class=\"label\"> 22. </span> <cite> Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015;33(17):1974\u201382. 10.1200/JCO.2014.59.4358 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1200/JCO.2014.59.4358\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4980573/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/25605845/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Immune%20Checkpoint%20Blockade%20in%20Cancer%20Therapy&amp;author=MA%20Postow&amp;author=MK%20Callahan&amp;author=JD%20Wolchok&amp;volume=33&amp;issue=17&amp;publication_year=2015&amp;pages=1974-82&amp;pmid=25605845&amp;doi=10.1200/JCO.2014.59.4358&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref023\"> <span class=\"label\"> 23. </span> <cite> Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124\u20138. 10.1126/science.aaa1348 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1126/science.aaa1348\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4993154/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/25765070/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Cancer%20immunology.%20Mutational%20landscape%20determines%20sensitivity%20to%20PD-1%20blockade%20in%20non-small%20cell%20lung%20cancer&amp;author=NA%20Rizvi&amp;author=MD%20Hellmann&amp;author=A%20Snyder&amp;author=P%20Kvistborg&amp;author=V%20Makarov&amp;volume=348&amp;issue=6230&amp;publication_year=2015&amp;pages=124-8&amp;pmid=25765070&amp;doi=10.1126/science.aaa1348&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref024\"> <span class=\"label\"> 24. </span> <cite> Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350(6257):207\u201311. 10.1126/science.aad0095 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1126/science.aad0095\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC5054517/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26359337/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Genomic%20correlates%20of%20response%20to%20CTLA-4%20blockade%20in%20metastatic%20melanoma&amp;author=EM%20Van%20Allen&amp;author=D%20Miao&amp;author=B%20Schilling&amp;author=SA%20Shukla&amp;author=C%20Blank&amp;volume=350&amp;issue=6257&amp;publication_year=2015&amp;pages=207-11&amp;pmid=26359337&amp;doi=10.1126/science.aad0095&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref025\"> <span class=\"label\"> 25. </span> <cite> Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509\u201320. 10.1056/NEJMoa1500596 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1056/NEJMoa1500596\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4481136/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26028255/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=PD-1%20Blockade%20in%20Tumors%20with%20Mismatch-Repair%20Deficiency&amp;author=DT%20Le&amp;author=JN%20Uram&amp;author=H%20Wang&amp;author=BR%20Bartlett&amp;author=H%20Kemberling&amp;volume=372&amp;issue=26&amp;publication_year=2015&amp;pages=2509-20&amp;pmid=26028255&amp;doi=10.1056/NEJMoa1500596&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pone.0179170.ref026\"> <span class=\"label\"> 26. </span> <cite> Sloan EA, Ring KL, Willis BC, Modesitt SC, Mills AM. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors. Am J Surg Pathol. 2016. 10.1097/PAS.0000000000000783 . </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1097/PAS.0000000000000783\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/27984238/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Am%20J%20Surg%20Pathol&amp;title=PD-L1%20Expression%20in%20Mismatch%20Repair-deficient%20Endometrial%20Carcinomas,%20Including%20Lynch%20Syndrome-associated%20and%20MLH1%20Promoter%20Hypermethylated%20Tumors&amp;author=EA%20Sloan&amp;author=KL%20Ring&amp;author=BC%20Willis&amp;author=SC%20Modesitt&amp;author=AM%20Mills&amp;publication_year=2016&amp;pmid=27984238&amp;doi=10.1097/PAS.0000000000000783&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> </ul> </section> </section> <section class=\"associated-data\" id=\"_ad93_\" lang=\"en\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"_ad93_-anchor\"> </a> Associated Data </h2> <p class=\"font-secondary\"> <em> This section collects any data citations, data availability statements, or supplementary materials included in this article. </em> </p> <section class=\"supplementary-materials\" id=\"_adsm93_\" lang=\"en\"> <h3 class=\"pmc_sec_title\"> Supplementary Materials </h3> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material1_reqid_\"> <div class=\"caption p\"> <span> S1 Table. Summary of potentially actionable genomic alterations. </span> <p> Detailed information on potentially therapeutically actionable alterations identified in 12 SCLC tumors. </p> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/5460863/bin/pone.0179170.s001.xlsx\"> Click here for additional data file. </a> <sup> (45.6KB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material2_reqid_\"> <div class=\"caption p\"> <span> S1 File. Protocol. </span> <p> The protocol for this pilot study. </p> <p> (PDF) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/5460863/bin/pone.0179170.s002.pdf\"> Click here for additional data file. </a> <sup> (491.3KB, pdf) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material3_reqid_\"> <div class=\"caption p\"> <span> S2 File. TREND checklist. </span> <p> The completed TREND checklist submitted for this manuscript. </p> <p> (PDF) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/5460863/bin/pone.0179170.s003.pdf\"> Click here for additional data file. </a> <sup> (98.1KB, pdf) </sup> </div> </div> </section> </section> <section class=\"data-availability-statement\" id=\"_adda93_\" lang=\"en\"> <h3 class=\"pmc_sec_title\"> Data Availability Statement </h3> <p> All NGS files are available from dbGaP under accession, phs001366.v1.p1 ( <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001366.v1.p1\" rel=\"noopener noreferrer\" target=\"_blank\"> https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001366.v1.p1 </a> ). </p> </section> </section> </section> <footer class=\"p courtesy-note font-secondary font-sm text-center\"> <hr class=\"headless\"/> <p> Articles from PLoS ONE are provided here courtesy of <strong> PLOS </strong> </p> </footer> </section> </article> </main> </div> </div> </div> <div class=\"pmc-sidenav desktop:grid-col-4 display-flex\"> <section aria-label=\"Article resources and navigation\" class=\"pmc-sidenav__container\"> <button class=\"usa-button pmc-sidenav__container__close usa-button--unstyled\" type=\"button\"> <img alt=\"Close\" role=\"img\" src=\"/static/img/usa-icons/close.svg\"/> </button> <div class=\"display-none desktop:display-block\"> <section class=\"margin-top-4 desktop:margin-top-0\"> <h2 class=\"margin-top-0\"> ACTIONS </h2> <ul class=\"usa-list usa-list--unstyled usa-list--actions\"> <li> <a class=\"usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1\" href=\"https://doi.org/10.1371/journal.pone.0179170\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#launch\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1 padding-right-2\"> View on publisher site </span> </a> </li> <li> <a class=\"usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1\" href=\"pdf/pone.0179170.pdf\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#file_download\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1\"> PDF (2.5 MB) </span> </a> </li> <li> <button aria-label=\"Open dialog with citation text in different styles\" class=\"usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1\" role=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#format_quote\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1 button-label\"> Cite </span> </button> </li> <li> <button aria-label=\"Save article in MyNCBI collections.\" class=\"usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3 usa-icon--bookmark-full\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/action-bookmark-full.svg#icon\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3 usa-icon--bookmark-empty\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/action-bookmark-empty.svg#icon\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1\"> Collections </span> </button> </li> <li class=\"pmc-permalink\"> <button aria-expanded=\"false\" aria-haspopup=\"true\" aria-label=\"Show article permalink\" class=\"usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#share\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1 button-label\"> Permalink </span> </button> <div class=\"pmc-permalink__dropdown\" hidden=\"\"> <div class=\"pmc-permalink__dropdown__container\"> <h2 class=\"usa-modal__heading margin-top-0 margin-bottom-2\"> PERMALINK </h2> <div class=\"pmc-permalink__dropdown__content\"> <input aria-label=\"Article permalink\" class=\"usa-input\" type=\"text\" value=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5460863/\"/> <button aria-expanded=\"false\" class=\"usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0\" title=\"Copy article permalink\"> <svg aria-hidden=\"true\" class=\"usa-icon\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#content_copy\"> </use> </svg> <span class=\"margin-left-1\"> Copy </span> </button> </div> </div> </div> </li> </ul> </section> </div> <section class=\"pmc-resources margin-top-6 desktop:margin-top-4\"> <h2 class=\"margin-top-0\"> RESOURCES </h2> <div class=\"usa-accordion usa-accordion--multiselectable\"> <h3 class=\"usa-accordion__heading\"> <button aria-controls=\"resources-similar-articles\" aria-expanded=\"false\" class=\"usa-accordion__button\" type=\"button\"> Similar articles </button> </h3> <div class=\"usa-accordion__content usa-prose\" hidden=\"\" id=\"resources-similar-articles\"> </div> <h3 class=\"usa-accordion__heading\"> <button aria-controls=\"resources-cited-by-other-articles\" aria-expanded=\"false\" class=\"usa-accordion__button\" type=\"button\"> Cited by other articles </button> </h3> <div class=\"usa-accordion__content usa-prose\" hidden=\"\" id=\"resources-cited-by-other-articles\"> </div> <h3 class=\"usa-accordion__heading\"> <button aria-controls=\"resources-links-to-ncbi-databases\" aria-expanded=\"false\" class=\"usa-accordion__button\" type=\"button\"> Links to NCBI Databases </button> </h3> <div class=\"usa-accordion__content usa-prose\" hidden=\"\" id=\"resources-links-to-ncbi-databases\"> </div> </div> </section> <section class=\"usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4\"> <nav aria-label=\"On this page\" class=\"usa-in-page-nav__nav\"> <h2 class=\"usa-in-page-nav__heading\" tabindex=\"0\"> On this page </h2> <ul class=\"usa-in-page-nav__list\"> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#abstract1\"> Abstract </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#sec005\"> Introduction </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#sec006\"> Materials and methods </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#sec011\"> Results </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#sec013\"> Discussion </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#sec014\"> Supporting information </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#ack1\"> Acknowledgments </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#notes1\"> Data Availability </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#funding-statement1\"> Funding Statement </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#ref-list1\"> References </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#_ad93_\"> Associated Data </a> </li> </ul> </nav> </section> </section> </div> <div aria-label=\"Citation Dialog\" class=\"overlay citation-dialog-overlay\" role=\"dialog\"> <div aria-hidden=\"true\" class=\"dialog citation-dialog\" role=\"document\"> <div class=\"display-inline-flex flex-align-center flex-justify width-full margin-bottom-2\"> <h2 class=\"usa-modal__heading margin-0\"> Cite </h2> <button class=\"usa-button usa-button--unstyled close-overlay text-black width-auto\" tabindex=\"1\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#close\"> </use> </svg> </button> </div> <div class=\"citation-text-block\"> <div class=\"citation-text margin-bottom-2\"> </div> <ul class=\"usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center\"> <li> <button class=\"usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus\" tabindex=\"2\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#content_copy\"> </use> </svg> <span> Copy </span> </button> </li> <li> <a class=\"usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button\" href=\"#\" role=\"button\" tabindex=\"3\" title=\"Download a file for external citation management software\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#file_download\"> </use> </svg> <span class=\"display-none mobile-lg:display-inline\"> Download .nbib </span> <span class=\"display-inline mobile-lg:display-none\"> .nbib </span> </a> </li> <li> <div class=\"display-inline-flex flex-align-center\"> <label class=\"usa-label margin-top-0\"> Format: </label> <select aria-label=\"Format\" class=\"usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4\" tabindex=\"4\"> <option value=\"AMA\"> AMA </option> <option value=\"APA\"> APA </option> <option value=\"MLA\"> MLA </option> <option selected=\"selected\" value=\"NLM\"> NLM </option> </select> </div> </li> </ul> <div class=\"dots-loading-indicator citation-loading-indicator\"> <div class=\"dot dot-1\"> </div> <div class=\"dot dot-2\"> </div> <div class=\"dot dot-3\"> </div> </div> </div> </div> </div> <div class=\"overlay collections-dialog-overlay\" role=\"dialog\"> <div aria-hidden=\"true\" class=\"dialog collections-dialog\" id=\"collections-action-dialog\" role=\"document\"> <div class=\"display-inline-flex flex-align-center flex-justify width-full margin-bottom-2\"> <h2 class=\"usa-modal__heading margin-0\"> Add to Collections </h2> </div> <div class=\"collections-action-panel action-panel\"> <form class=\"usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors\" id=\"collections-action-dialog-form\"> <fieldset class=\"usa-fieldset margin-bottom-2\"> <div class=\"usa-radio\"> <input class=\"usa-radio__input usa-radio__input--tile collections-new margin-top-0\" id=\"collections-action-dialog-new\" name=\"collections\" type=\"radio\" value=\"new\"/> <label class=\"usa-radio__label\" for=\"collections-action-dialog-new\"> Create a new collection </label> </div> <div class=\"usa-radio\"> <input checked=\"true\" class=\"usa-radio__input usa-radio__input--tile collections-existing\" id=\"collections-action-dialog-existing\" name=\"collections\" type=\"radio\" value=\"existing\"/> <label class=\"usa-radio__label\" for=\"collections-action-dialog-existing\"> Add to an existing collection </label> </div> </fieldset> <fieldset class=\"usa-fieldset margin-bottom-2\"> <div class=\"action-panel-control-wrap new-collections-controls\"> <label class=\"usa-label margin-top-0\" for=\"collections-action-dialog-add-to-new\"> Name your collection <abbr class=\"usa-hint usa-hint--required text-no-underline\" title=\"required\"> * </abbr> </label> <input class=\"usa-input collections-action-add-to-new\" id=\"collections-action-dialog-add-to-new\" maxlength=\"\" name=\"add-to-new-collection\" pattern='[^\"&amp;=&lt;&gt;/]*' required=\"\" title='The following characters are not allowed in the Name field: \"&amp;=&lt;&gt;/' type=\"text\"/> </div> <div class=\"action-panel-control-wrap existing-collections-controls\"> <label class=\"usa-label margin-top-0\" for=\"collections-action-dialog-add-to-existing\"> Choose a collection </label> <select class=\"usa-select collections-action-add-to-existing\" id=\"collections-action-dialog-add-to-existing\"> </select> <div class=\"collections-retry-load-on-error usa-input-error-message selection-validation-message\"> Unable to load your collection due to an error <br/> <a href=\"#\"> Please try again </a> </div> </div> </fieldset> <div class=\"display-inline-flex\"> <button class=\"usa-button margin-top-0 action-panel-submit\" type=\"submit\"> Add </button> <button aria-label=\"Close 'Add to Collections' panel\" class=\"usa-button usa-button--outline margin-top-0 action-panel-cancel\" ref=\"linksrc=close_collections_panel\"> Cancel </button> </div> </form> </div> </div> </div> </div> </div> </div> <footer class=\"ncbi-footer ncbi-dark-background\"> <div class=\"ncbi-footer__icon-section\"> <div class=\"ncbi-footer__social-header\"> Follow NCBI </div> <div class=\"grid-container ncbi-footer__ncbi-social-icons-container\"> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://twitter.com/ncbi\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"40\" viewbox=\"0 0 40 40\" width=\"40\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI on X (formerly known as Twitter) </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://www.facebook.com/ncbi.nlm\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"29\" viewbox=\"0 0 16 29\" width=\"16\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI on Facebook </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://www.linkedin.com/company/ncbinlm\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"23\" viewbox=\"0 0 26 24\" width=\"25\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z\"> </path> <path d=\"M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z\"> </path> <path d=\"M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI on LinkedIn </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://github.com/ncbi\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"27\" viewbox=\"0 0 28 28\" width=\"28\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI on GitHub </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://ncbiinsights.ncbi.nlm.nih.gov/\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"26\" viewbox=\"0 0 27 27\" width=\"26\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z\"> </path> <path d=\"M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z\"> </path> <path d=\"M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI RSS feed </span> </a> </div> </div> <div class=\"grid-container ncbi-footer__container\"> <div class=\"grid-row ncbi-footer__main-content-container\"> <div class=\"ncbi-footer__column\"> <p class=\"ncbi-footer__circled-icons-heading\"> Connect with NLM </p> <div class=\"ncbi-footer__circled-icons-list\"> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--circled\" href=\"https://twitter.com/nlm_nih\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"32\" viewbox=\"0 0 40 40\" width=\"32\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z\"> </path> </svg> <span class=\"usa-sr-only\"> NLM on X (formerly known as Twitter) </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--circled\" href=\"https://www.facebook.com/nationallibraryofmedicine\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"24\" viewbox=\"0 0 13 24\" width=\"13\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z\"> </path> </svg> <span class=\"usa-sr-only\"> NLM on Facebook </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--circled\" href=\"https://www.youtube.com/user/NLMNIH\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"15\" viewbox=\"0 0 21 15\" width=\"21\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z\" fill=\"white\"> </path> </svg> <span class=\"usa-sr-only\"> NLM on YouTube </span> </a> </div> </div> <address class=\"ncbi-footer__address ncbi-footer__column\"> <p> <a class=\"usa-link usa-link--external\" href=\"https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508, -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508! 4d-77.0988323\" rel=\"noopener noreferrer\" target=\"_blank\"> National Library of Medicine <br/> 8600 Rockville Pike <br/> Bethesda, MD 20894 </a> </p> </address> <ul class=\"usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column\"> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nlm.nih.gov/web_policies.html\"> Web Policies </a> </li> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office\"> FOIA </a> </li> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--external usa-link--alt ncbi-footer__link\" href=\"https://www.hhs.gov/vulnerability-disclosure-policy/index.html\" rel=\"noreferrer noopener\" target=\"_blank\"> HHS Vulnerability Disclosure </a> </li> </ul> <ul class=\"usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column\"> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://support.nlm.nih.gov/?pagename=cloudpmc-viewer%3Apmc%3Aarticle%3Ajournal\"> Help </a> </li> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nlm.nih.gov/accessibility.html\"> Accessibility </a> </li> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nlm.nih.gov/careers/careers.html\"> Careers </a> </li> </ul> </div> <div class=\"grid-row grid-col-12\"> <ul class=\"ncbi-footer__bottom-links-list\"> <li class=\"ncbi-footer__bottom-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nlm.nih.gov/\"> NLM </a> </li> <li class=\"ncbi-footer__bottom-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nih.gov/\"> NIH </a> </li> <li class=\"ncbi-footer__bottom-list-item\"> <a class=\"usa-link usa-link--external usa-link--alt ncbi-footer__link\" href=\"https://www.hhs.gov/\" rel=\"noreferrer noopener\" target=\"_blank\"> HHS </a> </li> <li class=\"ncbi-footer__bottom-list-item\"> <a class=\"usa-link usa-link--external usa-link--alt ncbi-footer__link\" href=\"https://www.usa.gov/\" rel=\"noreferrer noopener\" target=\"_blank\"> USA.gov </a> </li> </ul> </div> </div> </footer> <div id=\"ZN_dikYWqsjiUWN0Q5\"> </div> <button class=\"back-to-top\"> <label> Back to Top </label> <svg aria-hidden=\"true\" class=\"usa-icon order-0\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#arrow_upward\"> </use> </svg> </button> <div class=\"fake-body-scroll\"> </div> <div class=\"fake-body-scroll\"> </div> <div class=\"QSIFeedbackButton\"> <button aria-label=\"Tell us what you think!\" id=\"QSIFeedbackButton-btn\" role=\"button\"> <img alt=\"Tell us what you think!\" src=\"https://iad1.qualtrics.com/WRQualtricsSiteIntercept/Graphic.php?IM=IM_3xWqwNkIHc7cA0S\"/> </button> </div> </body> </html>) and a list of known data repositories (bigd.big.ac.cn, massive.ucsd.edu, www.ebi.ac.uk, www.iprox.cn, proteomecentral.proteomexchange.org, www.proteomexchange.org, pdc.cancer.gov, doi.org, www.ncbi.nlm.nih.gov). Given this information, please return a JSON array of objects where each object has the following structure:\n- `dataset_identifier`: The dataset identifier (a code). If not found, set it to \"n/a\".\n- `repository_reference`: The URL or reference to the data repository. If not found, set it to \"n/a\".\n\nPlease follow these strict instructions:\n- The output must be a valid JSON array of objects.\n- Each object must contain the keys `dataset_identifier` and `repository_reference`.\n- Any other output format will be considered invalid."}]}]